{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Lifestyle-mediated weight loss reverses steatohepatitis in adults with baseline biopsy-confirmed MASH.", "entry_form": "claim", "gradeable_restatement": "Assigned lifestyle weight-loss treatment improves steatohepatitis histology in adults with baseline biopsy-confirmed MASH over 24–104 weeks.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline age, BMI, metabolic disease, biopsy diagnosis and fibrosis stage, medication stability, assigned diet/exercise support and prespecified follow-up; achieved-loss and histologic responders do not determine eligibility.", "determinable_before_outcome": true, "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.", "action": "retained" } ], "original_claim": "Lifestyle-mediated weight loss reverses steatohepatitis in adults with baseline biopsy-confirmed MASH.", "restatement_note": "This makes the preregistered primary SC2 assignment estimand explicit. It preserves inflammation/ballooning rather than fat alone, the baseline MASH population and follow-up. It does not claim that achieved kilograms independently mediate every response, that all patients respond, or that fibrosis and liver-death prevention have been established." }, "hypothesis": { "name": "Lifestyle Weight Loss and MASH Reversal", "central_claim": "Assigned lifestyle weight-loss treatment improves steatohepatitis histology in adults with baseline biopsy-confirmed MASH over 24–104 weeks.", "proposed_mechanism": "Lifestyle-mediated weight loss reverses steatohepatitis in adults with baseline biopsy-confirmed MASH.", "claimed_scope": "Baseline biopsy-confirmed adult MASH, assigned lifestyle weight-loss package versus concurrent usual-care/education comparator, paired inflammation/ballooning histology at 24–104 weeks. Fat, fibrosis and hard liver events are separate companions.", "claimed_level": [ "response" ], "is_conjunctive": false, "conjunctive_note": "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint." }, "rubric_routing": { "primary_rubric": "06-metabolism-aging.md", "secondary_rubrics": [], "index_notes_applied": [ "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint." ], "rubric_fit_note": "The frozen framework has no dedicated clinical hepatology rubric. Rubric 06 governs proxy-versus-phenotype interpretation with an explicit clinical adaptation: an assigned treatment changing paired steatohepatitis pathology is a disease phenotype perturbation, rather than an aging/lifespan claim. Literal caps and ladder remain unchanged. A biopsy fat component is scored as its own measured pathology in SC1, not as full MASH clinical success. Human treatment assignment establishes package sufficiency, not necessity or endogenous weight-mediated disease primacy." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Lifestyle weight loss reduces hepatic fat.", "subclaim_type": "mechanism", "scope": "Baseline biopsy-confirmed MASH; assigned lifestyle strategy before achieved loss", "claimed_scope": "Baseline biopsy-confirmed MASH; assigned lifestyle strategy before achieved loss", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled imaging and metabolic studies", "hsef_level": "Δ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Assigned lifestyle in the Promrat paired-biopsy trial reduced steatosis relative to education, and controlled exercise/metabolic work supports direct hepatic-fat change. This is a pathological fat component crossing within its measured scope, not a substitution of fat for steatohepatitis or hard-event benefit. The disease-stage and mediator boundaries prevent high-ladder generalization.", "rubric_adaptation": "Biopsy steatosis is the directly proposed pathological component; its measured change can cross the first scoped phenotype threshold, while imaging or blood markers alone cannot prove active MASH or fibrosis reversal." }, { "id": "SC2", "statement": "Assigned lifestyle weight-loss treatment improves steatohepatitis histology.", "subclaim_type": "sufficiency", "scope": "Baseline biopsy-confirmed MASH; inflammation and ballooning rather than liver fat alone; 24-104 weeks", "claimed_scope": "Baseline biopsy-confirmed MASH; inflammation and ballooning rather than liver fat alone; 24-104 weeks", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled paired-biopsy clinical trials", "hsef_level": "Δ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "The newer randomized energy-restriction/HIIT trial explicitly defines histologic resolution by inflammation 0–1 and ballooning 0, and reports improvements in these components and steatohepatitis relative to its control trajectory at about ten months. This supplies a first direct assigned clinical phenotype perturbation. Its Results report resolution in 9 treatment and 0 control participants (final sample 16 and 8); the eight treated participants who reduced ballooning to 0 are compatible with nine resolutions because entry required NAS of at least 4, not ballooning of at least 1. Its small final sample, within-arm component reporting without a printed between-group test, and higher baseline MRS liver fat in controls (24% versus 15%) constrain confidence. Promrat improves a composite NAS and steatosis but has nonsignificant assigned component differences, so it reinforces activity change without being counted as a second current-resolution confirmation. The other randomized standard-care-controlled paired-biopsy lifestyle trial found on targeted search (Eckard 2013) showed improvement in every arm without a between-arm difference, so the assigned-package effect is not yet consistently reproduced. Broader clinical contexts and isolated weight mediation remain unestablished.", "rubric_adaptation": "Require concurrent assigned lifestyle treatment and paired actual inflammation/ballooning histology within registered baseline adult MASH and 24–104 weeks. Current-resolution criteria and NAS composites remain distinct; treatment-bundle sufficiency does not isolate kilograms as mediator." }, { "id": "SC3", "statement": "Lifestyle weight-loss treatment reverses established fibrosis.", "subclaim_type": "generalization", "scope": "Baseline fibrosis stage specified; assigned treatment and paired biopsy", "claimed_scope": "Baseline fibrosis stage specified; assigned treatment and paired biopsy", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Controlled fibrosis improvement tests", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal.", "rubric_adaptation": "Require actual controlled fibrosis improvement at specified baseline stage; stiffness, collagen markers and response-selected biopsies are not that endpoint." }, { "id": "SC4", "statement": "Biomarker or liver-fat reduction establishes prevention of cirrhosis and liver death.", "subclaim_type": "generalization", "scope": "Hard clinical follow-up; no surrogate substitution", "claimed_scope": "Hard clinical follow-up; no surrogate substitution", "governing_rubric": "06-metabolism-aging.md", "key_evidence_anchor": "Event-based clinical follow-up", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Quoted boundary and upward audit below.", "rationale": "Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped.", "rubric_adaptation": "Require hepatic clinical events or credible independently convergent clinical causal evidence; nonhepatic cardiovascular events and short-trial absence of events cannot replace cirrhosis/liver-death follow-up." } ], "aggregation_rule": "primary-subclaim", "aggregation_preregistered": true, "aggregation_rationale": "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.", "primary_subclaim_id": "SC2", "aggregation_derivation": "The registered primary SC2 reaches Δ with Moderate confidence: a small randomized lifestyle package changes explicit steatohepatitis histology, while the older trial offers broader activity support. Direct original-body examination prevents calling fat-only NAS changes full resolution. Evidence does not yet map sufficiently broad baseline contexts or isolate achieved weight as the causal mediator to reach Ε or mechanistically narrowed convergence. Separate Γ fibrosis and surrogate-to-event companions do not erase the positive registered clinical phenotype.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Δ", "scope_matched_would_return": "Δ", "note": "Separate narrow successes do not replace the preregistered full-scope gate." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 2, "model_id": "M1", "is_nominal": true, "name": "Energy balance and adiposity change reverse steatohepatitis", "core_claim": "Lifestyle packages change metabolic input and can improve active histology.", "explains_what_nominal_does_not": "Lifestyle packages change metabolic input and can improve active histology.", "strongest_supporting_evidence": [ "The newer histology trial and older assigned NAS/steatosis trial establish genuine package effects." ], "strongest_contradictory_evidence": [ "Weight-histology correlations do not isolate the mediator; fibrosis and several component or comparator endpoints remain null.", "The randomized standard-care-controlled paired-biopsy trial of Eckard 2013 [61] found improvement in every arm without a between-arm difference." ], "hsef_level_for_this_model": "Δ", "rationale": "The newer histology trial and older assigned NAS/steatosis trial establish genuine package effects. Weight-histology correlations do not isolate the mediator; fibrosis and several component or comparator endpoints remain null. The randomized standard-care-controlled paired-biopsy trial of Eckard 2013 [61] found improvement in every arm without a between-arm difference." }, { "rank_in_tournament": 1, "model_id": "M2", "is_nominal": false, "name": "Fat, inflammation and fibrosis have distinct treatment responses", "core_claim": "Pathological components respond differently to lifestyle, activity and drugs.", "explains_what_nominal_does_not": "Pathological components respond differently to lifestyle, activity and drugs.", "strongest_supporting_evidence": [ "Promrat has fat/NAS positives but assigned component and fibrosis nulls; the newer trial has activity benefit without average fibrosis improvement, and the F4 drug trial has fat/weight benefit without histologic resolution." ], "strongest_contradictory_evidence": [ "This is a component-response model, not proof of one unique upstream molecular pathway or inevitable irreversibility." ], "hsef_level_for_this_model": "Δ", "rationale": "Promrat has fat/NAS positives but assigned component and fibrosis nulls; the newer trial has activity benefit without average fibrosis improvement, and the F4 drug trial has fat/weight benefit without histologic resolution. This is a component-response model, not proof of one unique upstream molecular pathway or inevitable irreversibility." }, { "rank_in_tournament": 3, "model_id": "M3", "is_nominal": false, "name": "Achieved loss and host adherence confound mediator attribution", "core_claim": "Baseline biology and adherence affect achieved loss and histologic response together.", "explains_what_nominal_does_not": "Baseline biology and adherence affect achieved loss and histologic response together.", "strongest_supporting_evidence": [ "Uncontrolled achieved-at-least-10% cohorts and posthoc drug-responder analyses cannot isolate kilograms from cointerventions." ], "strongest_contradictory_evidence": [ "Confounding of achieved loss does not explain away randomized lifestyle-package contrasts." ], "hsef_level_for_this_model": "Γ", "rationale": "Uncontrolled achieved-at-least-10% cohorts and posthoc drug-responder analyses cannot isolate kilograms from cointerventions. Confounding of achieved loss does not explain away randomized lifestyle-package contrasts." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Baseline stage and intervention identity determine transfer", "core_claim": "Established fibrosis, cirrhosis and direct drug action differ from earlier active disease and lifestyle input.", "explains_what_nominal_does_not": "Established fibrosis, cirrhosis and direct drug action differ from earlier active disease and lifestyle input.", "strongest_supporting_evidence": [ "Noncirrhotic drug positives, F4 semaglutide nulls and surgery results map exposure/stage boundaries." ], "strongest_contradictory_evidence": [ "Cross-trial differences do not prove a treatment-by-stage interaction or establish every stage-specific lifestyle effect." ], "hsef_level_for_this_model": "Γ", "rationale": "Noncirrhotic drug positives, F4 semaglutide nulls and surgery results map exposure/stage boundaries. Cross-trial differences do not prove a treatment-by-stage interaction or establish every stage-specific lifestyle effect." }, { "rank_in_tournament": 5, "model_id": "M5", "is_nominal": false, "name": "Non-specific trial effects, regression to the mean and biopsy sampling variability explain small-trial histologic change", "core_claim": "Control and standard-care arms also improve; single-pathologist small samples and completer analyses magnify noise.", "explains_what_nominal_does_not": "The null between-arm contrast in Eckard 2013 [61], where every arm including standard care improved.", "strongest_supporting_evidence": [ "Promrat discusses control-arm histologic improvement and regression to the mean; Mucinski controls also lost liver fat; Eckard 2013 found improvement in every arm including standard care." ], "strongest_contradictory_evidence": [ "Randomized between-arm differences in [1] and [46] are not explained by non-specific effects." ], "hsef_level_for_this_model": "Γ", "rationale": "Control and standard-care arms also improve; single-pathologist small samples and completer analyses magnify noise. Randomized between-arm differences in [1] and [46] are not explained by this, but the null between-arm contrast in Eckard 2013 [61] is. Added by adversarial finding WL-4 (2026-11-02)." } ], "tournament_summary": "Descriptive comparison; does not modify the nominal score. Actual Promrat body PMID19827166 separates significant assigned NAS/steatosis change from nonsignificant assigned inflammation/ballooning and fibrosis. PMID38914313 supplies a newer explicit activity/resolution positive with unchanged average fibrosis. These contrasts favor component-specific response over a single universal weight-to-all-liver-outcomes mechanism.", "study_separating_rank1_from_rank2": "Actual Promrat body PMID19827166 separates significant assigned NAS/steatosis change from nonsignificant assigned inflammation/ballooning and fibrosis. PMID38914313 supplies a newer explicit activity/resolution positive with unchanged average fibrosis. These contrasts favor component-specific response over a single universal weight-to-all-liver-outcomes mechanism.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "19827166", "title": "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis.", "citation": "Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2010.", "doi": "10.1002/hep.23276", "pmcid": "PMC2799538", "url": "https://pubmed.ncbi.nlm.nih.gov/19827166/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19827166/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PROMRAT-LIFESTYLE", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph11, 0:Methods:paragraph13, 0:Methods:paragraph14, 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph9, 1:Results:paragraph12. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A 31-person randomized 48-week lifestyle-versus-education trial improved weight, NAS and steatosis; assigned inflammation/ballooning differences were nonsignificant and fibrosis unchanged.", "what_it_does_not_show": "Actual Methods/Results use a composite NAS endpoint, not current resolution criteria; positive achieved-loss component strata are nonrandomized and cannot prove isolated weight mediation.", "confounders_present": [ "Actual Methods/Results use a composite NAS endpoint, not current resolution criteria; positive achieved-loss component strata are nonrandomized and cannot prove isolated weight mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 2, "pmid": "25865049", "title": "Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.", "citation": "Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015.", "doi": "10.1053/j.gastro.2015.04.005", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/25865049/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25865049/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "Prospective 293-person lifestyle cohort with 261 paired biopsies found steatohepatitis resolution and fibrosis regression associated with greater achieved weight loss.", "what_it_does_not_show": "Achieved at-least-10% subgroup is not a randomized treatment or baseline scope; no control and missing biopsies limit causal attribution and independence.", "confounders_present": [ "Achieved at-least-10% subgroup is not a randomized treatment or baseline scope; no control and missing biopsies limit causal attribution and independence." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 3, "pmid": "26849287", "title": "Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.", "citation": "Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology (Baltimore, Md.). 2016.", "doi": "10.1002/hep.28484", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26849287/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26849287/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A split development/validation analysis predicts histologic resolution using weight loss, metabolic status, ALT and baseline features.", "what_it_does_not_show": "Shares the lifestyle cohort; posttreatment predictors and internal validation are not a new causal trial or proof of prevented clinical events.", "confounders_present": [ "Shares the lifestyle cohort; posttreatment predictors and internal validation are not a new causal trial or proof of prevented clinical events." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 4, "pmid": "27862096", "title": "Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.", "citation": "Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2017.", "doi": "10.1111/apt.13860", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27862096/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27862096/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Shared lifestyle-cohort posthoc analysis associates histology improvement with eGFR change over 52 weeks.", "what_it_does_not_show": "Renal correlation is not independent randomized evidence or cirrhosis/liver-death prevention; shared participants remain one study.", "confounders_present": [ "Renal correlation is not independent randomized evidence or cirrhosis/liver-death prevention; shared participants remain one study." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 5, "pmid": "21794038", "title": "Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels.", "citation": "Promrat K, Longato L, Wands JR et al. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatology research : the official journal of the Japan Society of Hepatology. 2011.", "doi": "10.1111/j.1872-034X.2011.00815.x", "pmcid": "PMC4550290", "url": "https://pubmed.ncbi.nlm.nih.gov/21794038/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21794038/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PROMRAT-LIFESTYLE", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Lifestyle-versus-education paired biopsies show weight-associated changes in ceramide expression/serum measures.", "what_it_does_not_show": "Shares the primary lifestyle trial; molecular correlation is not ceramide necessity or an additional independent histology efficacy line.", "confounders_present": [ "Shares the primary lifestyle trial; molecular correlation is not ceramide necessity or an additional independent histology efficacy line." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 6, "pmid": "27521509", "title": "Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.", "citation": "Houghton D, Thoma C, Hallsworth K et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017.", "doi": "10.1016/j.cgh.2016.07.031", "pmcid": "PMC5196006", "url": "https://pubmed.ncbi.nlm.nih.gov/27521509/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27521509/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27521509", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Exercise at maintained weight reduced hepatic triglyceride and visceral fat in 24 biopsy-confirmed NASH adults over 12 weeks, with inflammation/fibrosis markers unchanged.", "what_it_does_not_show": "No repeated biopsy and below registered 24-week gate; liver-fat improvement cannot establish steatohepatitis or fibrosis reversal.", "confounders_present": [ "No repeated biopsy and below registered 24-week gate; liver-fat improvement cannot establish steatohepatitis or fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 7, "pmid": "38847589", "title": "Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease.", "citation": "Cuthbertson DJ, Keating SE, Pugh CJA et al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2024.", "doi": "10.1111/liv.15947", "pmcid": "PMC11365804", "url": "https://pubmed.ncbi.nlm.nih.gov/38847589/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38847589/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38847589", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Pooled exercise trials increased odds of a 30% MRI-fat reduction with little weight loss and improved fitness.", "what_it_does_not_show": "The endpoint is an imaging surrogate, not measured histologic response or fibrosis improvement; pooled parents do not create independent clinical histology lines.", "confounders_present": [ "The endpoint is an imaging surrogate, not measured histologic response or fibrosis improvement; pooled parents do not create independent clinical histology lines." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [ "POOLED-THREE-EXERCISE-PARENTS" ] }, { "n": 8, "pmid": "26265792", "title": "Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial.", "citation": "Hallsworth K, Thoma C, Hollingsworth KG et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clinical science (London, England : 1979). 2015.", "doi": "10.1042/CS20150308", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26265792/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26265792/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26265792", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Twelve-week HIIT in 23 NAFLD adults reduced liver fat and improved selected cardiac/body measures, with glucose-control nulls.", "what_it_does_not_show": "No paired NASH histology and short follow-up; fat reduction does not imply ballooning/inflammation reversal or hard liver outcomes.", "confounders_present": [ "No paired NASH histology and short follow-up; fat reduction does not imply ballooning/inflammation reversal or hard liver outcomes." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 9, "pmid": "29947322", "title": "Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.", "citation": "Katsagoni CN, Papatheodoridis GV, Ioannidou P et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. The British journal of nutrition. 2018.", "doi": "10.1017/S000711451800137X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29947322/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29947322/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29947322", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Six-month Mediterranean diet/lifestyle counseling reduced weight and selected ALT/stiffness measures versus written advice.", "what_it_does_not_show": "Ultrasound NAFLD and elastography are not biopsy-confirmed MASH resolution/fibrosis; bundled diet, exercise and sleep cannot isolate weight mediation.", "confounders_present": [ "Ultrasound NAFLD and elastography are not biopsy-confirmed MASH resolution/fibrosis; bundled diet, exercise and sleep cannot isolate weight mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 10, "pmid": "36549296", "title": "Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial.", "citation": "Ezpeleta M, Gabel K, Cienfuegos S et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell metabolism. 2023.", "doi": "10.1016/j.cmet.2022.12.001", "pmcid": "PMC9812925", "url": "https://pubmed.ncbi.nlm.nih.gov/36549296/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36549296/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36549296", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Fasting-plus-exercise reduced liver fat versus exercise/control in an 80-person three-month trial, with several metabolic and fibrosis-score nulls.", "what_it_does_not_show": "No biopsy MASH and short exposure; no clear added benefit over fasting alone, and scores cannot establish fibrosis reversal.", "confounders_present": [ "No biopsy MASH and short exposure; no clear added benefit over fasting alone, and scores cannot establish fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 11, "pmid": "42805146", "title": "A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial.", "citation": "Dallio M, Romeo M, Di Nardo F et al. A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial. Clinical nutrition (Edinburgh, Scotland). 2026.", "doi": "10.1016/j.clnu.2026.106800", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42805146/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42805146/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42805146", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "An 18-month multidisciplinary MASLD trial improved adherence, weight and liver imaging/stiffness and reported fewer acute cardiovascular events.", "what_it_does_not_show": "No paired MASH biopsy or hard hepatic endpoint is established from the abstract; cardiovascular events are distinct from cirrhosis/liver-death prevention and component mediation.", "confounders_present": [ "No paired MASH biopsy or hard hepatic endpoint is established from the abstract; cardiovascular events are distinct from cirrhosis/liver-death prevention and component mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 12, "pmid": "41933392", "title": "Isocaloric-restricted traditional Jiangnan diet combined with physical exercise on non-alcoholic fatty liver disease: a randomized controlled trial.", "citation": "Wu Y, Li L, Zhang X et al. Isocaloric-restricted traditional Jiangnan diet combined with physical exercise on non-alcoholic fatty liver disease: a randomized controlled trial. Nutrition & metabolism. 2026.", "doi": "10.1186/s12986-026-01105-4", "pmcid": "PMC13173863", "url": "https://pubmed.ncbi.nlm.nih.gov/41933392/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41933392/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41933392", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A 228-person diet/exercise trial found liver imaging/stiffness differences despite no between-group weight advantage.", "what_it_does_not_show": "FibroScan improvements are not histologic fibrosis reversal; MRI NAFLD differs from registered biopsy-MASH and diet components may act independently of weight.", "confounders_present": [ "FibroScan improvements are not histologic fibrosis reversal; MRI NAFLD differs from registered biopsy-MASH and diet components may act independently of weight." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 13, "pmid": "23273500", "title": "Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD).", "citation": "Scaglioni F, Marino M, Ciccia S et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and research in hepatology and gastroenterology. 2013.", "doi": "10.1016/j.clinre.2012.10.009", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23273500/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23273500/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23273500", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Twelve-person uncontrolled multidisciplinary program reduced weight, liver tests and noninvasive fat estimates over three months.", "what_it_does_not_show": "No control, biopsy or registered horizon; association does not establish steatohepatitis reversal or clinical events.", "confounders_present": [ "No control, biopsy or registered horizon; association does not establish steatohepatitis reversal or clinical events." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 14, "pmid": "19691668", "title": "Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.", "citation": "Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2009.", "doi": "10.1111/j.1365-2036.2009.04122.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/19691668/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/19691668/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19691668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Viusid-plus-diet/exercise versus diet/exercise in 60 biopsy-NAFLD adults improved NAS more with supplement; both groups improved histology.", "what_it_does_not_show": "Randomization isolates supplement addition rather than lifestyle efficacy; between-group fibrosis difference was nonsignificant, and shared cointerventions cannot prove weight necessity.", "confounders_present": [ "Randomization isolates supplement addition rather than lifestyle efficacy; between-group fibrosis difference was nonsignificant, and shared cointerventions cannot prove weight necessity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 15, "pmid": "15352910", "title": "A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.", "citation": "Harrison SA, Fincke C, Helinski D et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Alimentary pharmacology & therapeutics. 2004.", "doi": "10.1111/j.1365-2036.2004.02153.x", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/15352910/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/15352910/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID15352910", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Ten biopsy-NASH adults receiving orlistat plus dietary counseling showed observed weight/metabolic and selected paired-biopsy improvements over six months.", "what_it_does_not_show": "Uncontrolled drug/lifestyle combination and achieved-loss subgroup cannot establish assigned lifestyle causality or universal fibrosis reversal.", "confounders_present": [ "Uncontrolled drug/lifestyle combination and achieved-loss subgroup cannot establish assigned lifestyle causality or universal fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 16, "pmid": "22840293", "title": "Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.", "citation": "Lee YM, Low HC, Lim LG et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointestinal endoscopy. 2012.", "doi": "10.1016/j.gie.2012.05.023", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/22840293/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22840293/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID22840293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Balloon versus sham on matched diet/exercise lowered BMI and NAS in an 18-person six-month pilot.", "what_it_does_not_show": "No inflammation, ballooning or fibrosis score change; a NAS difference cannot automatically be called full MASH resolution, and device addition is a distinct intervention.", "confounders_present": [ "No inflammation, ballooning or fibrosis score change; a NAS difference cannot automatically be called full MASH resolution, and device addition is a distinct intervention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 17, "pmid": "39694202", "title": "Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial.", "citation": "Abad J, Llop E, Arias-Loste MT et al. Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2025.", "doi": "10.1016/j.cgh.2024.10.027", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39694202/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39694202/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39694202", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "ESG versus sham with matched lifestyle in 40 biopsy-MASH adults increased loss and reduced steatosis/stiffness at 72 weeks.", "what_it_does_not_show": "Between-group NAS and fibrosis were null; achieved-over-10% NAS subgroup is nonrandomized and does not rescue broad histology/fibrosis claims.", "confounders_present": [ "Between-group NAS and fibrosis were null; achieved-over-10% NAS subgroup is nonrandomized and does not rescue broad histology/fibrosis claims." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 18, "pmid": "41127972", "title": "Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.", "citation": "Noureddin M, Rinella M, Taub R et al. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Alimentary pharmacology & therapeutics. 2025.", "doi": "10.1111/apt.70382", "pmcid": "PMC12646629", "url": "https://pubmed.ncbi.nlm.nih.gov/41127972/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41127972/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MAESTRO secondary analysis associates achieved weight loss with larger resmetirom histology/imaging responses across selected diabetes-drug backgrounds.", "what_it_does_not_show": "Shared primary trial and nonrandomized achieved weight/background treatment cannot isolate lifestyle mediation or add an independent drug causal line.", "confounders_present": [ "Shared primary trial and nonrandomized achieved weight/background treatment cannot isolate lifestyle mediation or add an independent drug causal line." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 19, "pmid": "29779170", "title": "Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial.", "citation": "Bomhof MR, Parnell JA, Ramay HR et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. European journal of nutrition. 2019.", "doi": "10.1007/s00394-018-1721-2", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/29779170/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29779170/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29779170", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Nine-month oligofructose pilot in 14 biopsy-NASH adults improved NAS/steatosis independent of weight loss.", "what_it_does_not_show": "Steatosis-driven score change and small prebiotic exposure do not establish lifestyle-loss necessity or verified inflammation/ballooning reversal.", "confounders_present": [ "Steatosis-driven score change and small prebiotic exposure do not establish lifestyle-loss necessity or verified inflammation/ballooning reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 20, "pmid": "40258699", "title": "HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study.", "citation": "Wong VW, Neff GW, Di Bisceglie AM et al. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clinical and molecular hepatology. 2025.", "doi": "10.3350/cmh.2025.0145", "pmcid": "PMC12260645", "url": "https://pubmed.ncbi.nlm.nih.gov/40258699/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40258699/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40258699", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "HTD1801 hamster biopsy benefit accompanies an original human secondary analysis showing MRI/serum response proxies in presumed MASH.", "what_it_does_not_show": "Human histology was not measured; model results and predictive response criteria cannot establish patient MASH/fibrosis reversal.", "confounders_present": [ "Human histology was not measured; model results and predictive response criteria cannot establish patient MASH/fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 21, "pmid": "30610213", "title": "The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease.", "citation": "Saadati S, Hatami B, Yari Z et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. European journal of clinical nutrition. 2019.", "doi": "10.1038/s41430-018-0382-9", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/30610213/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30610213/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30610213", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Curcumin-plus-lifestyle trial showed several within-group changes but no superiority for main metabolic/steatosis measures versus lifestyle-placebo.", "what_it_does_not_show": "No paired biopsy or isolated lifestyle randomization; within-group fibrosis-score improvement is not a between-group clinical reversal effect.", "confounders_present": [ "No paired biopsy or isolated lifestyle randomization; within-group fibrosis-score improvement is not a between-group clinical reversal effect." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 22, "pmid": "26367736", "title": "Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.", "citation": "Aller R, Izaola O, Gómez S et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. European review for medical and pharmacological sciences. 2015.", "doi": "", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26367736/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26367736/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26367736", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Silymarin/vitamin-E-plus-diet versus diet reduced selected noninvasive indices in baseline biopsy-NAFLD over three months.", "what_it_does_not_show": "No follow-up biopsy and distinct exercise/supplement cointerventions; post-loss subgroup indices cannot establish fibrosis or histologic reversal.", "confounders_present": [ "No follow-up biopsy and distinct exercise/supplement cointerventions; post-loss subgroup indices cannot establish fibrosis or histologic reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 23, "pmid": "40305708", "title": "Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.", "citation": "Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England journal of medicine. 2025.", "doi": "10.1056/NEJMoa2413258", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/40305708/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40305708/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40305708", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "ESSENCE randomized semaglutide 2.4 mg weekly in biopsy-MASH; the first 800 at 72 weeks had greater histologic resolution and fibrosis improvement than placebo.", "what_it_does_not_show": "Distinct drug exposure and interim histology do not establish lifestyle mediation or the ongoing 240-week clinical-event result; pain endpoint was null and GI events more common.", "confounders_present": [ "Distinct drug exposure and interim histology do not establish lifestyle mediation or the ongoing 240-week clinical-event result; pain endpoint was null and GI events more common." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 24, "pmid": "36934740", "title": "Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.", "citation": "Loomba R, Abdelmalek MF, Armstrong MJ et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The lancet. Gastroenterology & hepatology. 2023.", "doi": "10.1016/S2468-1253(23)00068-7", "pmcid": "PMC10792518", "url": "https://pubmed.ncbi.nlm.nih.gov/36934740/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36934740/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36934740", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph10, 1:Methods:paragraph11, 1:Methods:paragraph15, 2:Results:paragraph5, 2:Results:paragraph8, 2:Results:paragraph9, 2:Results:paragraph11, 2:Results:paragraph15, 2:Results:paragraph24. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "In 71 compensated F4 patients, 48-week semaglutide reduced weight and MRI fat but did not significantly improve biopsy fibrosis, NASH resolution or component scores.", "what_it_does_not_show": "Selected original Methods/Results confirm stage-specific dissociation; absence of decompensation in this small short trial is not prevention proof and biopsy availability differed by arm.", "confounders_present": [ "Selected original Methods/Results confirm stage-specific dissociation; absence of decompensation in this small short trial is not prevention proof and biopsy availability differed by arm." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 25, "pmid": "33185364", "title": "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.", "citation": "Newsome PN, Buchholtz K, Cusi K et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. The New England journal of medicine. 2021.", "doi": "10.1056/NEJMoa2028395", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33185364/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33185364/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SEMA-DAILY-NCT02970942", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "A 320-person daily semaglutide biopsy trial found greater NASH resolution at the highest dose but a nonsignificant fibrosis endpoint at 72 weeks.", "what_it_does_not_show": "Daily dosing and drug action differ from lifestyle; fibrosis null cannot be replaced by steatosis or posthoc continuous-image improvement.", "confounders_present": [ "Daily dosing and drug action differ from lifestyle; fibrosis null cannot be replaced by steatosis or posthoc continuous-image improvement." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 26, "pmid": "32553765", "title": "Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis.", "citation": "Lassailly G, Caiazzo R, Ntandja-Wandji LC et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020.", "doi": "10.1053/j.gastro.2020.06.006", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/32553765/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32553765/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32553765", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A prospective bariatric cohort found substantial observed NASH resolution and fibrosis regression in available five-year biopsies.", "what_it_does_not_show": "Surgery is distinct from lifestyle, follow-up exceeds the registered primary horizon, and selective repeat biopsies without random control limit causal and hard-event inference.", "confounders_present": [ "Surgery is distinct from lifestyle, follow-up exceeds the registered primary horizon, and selective repeat biopsies without random control limit causal and hard-event inference." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 27, "pmid": "34762106", "title": "Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.", "citation": "Aminian A, Al-Kurd A, Wilson R et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021.", "doi": "10.1001/jama.2021.19569", "pmcid": "PMC8587225", "url": "https://pubmed.ncbi.nlm.nih.gov/34762106/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34762106/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34762106", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "SPLENDOR associated bariatric surgery with lower long-term major adverse liver and cardiovascular events in biopsy-fibrotic NASH.", "what_it_does_not_show": "Weighted observational surgery comparison is not randomized lifestyle-event evidence; raw and adjusted risk differences are different estimands, and perioperative deaths remain relevant.", "confounders_present": [ "Weighted observational surgery comparison is not randomized lifestyle-event evidence; raw and adjusted risk differences are different estimands, and perioperative deaths remain relevant." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 28, "pmid": "34570916", "title": "Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.", "citation": "Flint A, Andersen G, Hockings P et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Alimentary pharmacology & therapeutics. 2021.", "doi": "10.1111/apt.16608", "pmcid": "PMC9292692", "url": "https://pubmed.ncbi.nlm.nih.gov/34570916/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34570916/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34570916", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "Semaglutide in an MRI-defined NAFLD trial reduced liver fat without a significant liver-stiffness benefit.", "what_it_does_not_show": "MRI fat and stiffness are distinct from actual inflammation, ballooning and fibrosis biopsy; a drug trial does not isolate lifestyle or weight mediation.", "confounders_present": [ "MRI fat and stiffness are distinct from actual inflammation, ballooning and fibrosis biopsy; a drug trial does not isolate lifestyle or weight mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 29, "pmid": "37088093", "title": "Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.", "citation": "Verrastro O, Panunzi S, Castagneto-Gissey L et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet (London, England). 2023.", "doi": "10.1016/S0140-6736(23)00634-7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/37088093/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37088093/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37088093", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "BRAVES randomized 288 participants and found more one-year NASH resolution with either bariatric operation than lifestyle plus best medical care.", "what_it_does_not_show": "The lifestyle-arm response rate lacks an untreated comparator; surgery and cointerventions differ, and operative serious adverse events cannot be omitted.", "confounders_present": [ "The lifestyle-arm response rate lacks an untreated comparator; surgery and cointerventions differ, and operative serious adverse events cannot be omitted." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 30, "pmid": "35439567", "title": "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.", "citation": "Alkhouri N, Herring R, Kabler H et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of hepatology. 2022.", "doi": "10.1016/j.jhep.2022.04.003", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/35439567/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35439567/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35439567", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A 24-week semaglutide combination trial improved selected MRI-fat and metabolic measures with additional experimental drugs.", "what_it_does_not_show": "Combination components and noninvasive endpoints cannot establish lifestyle or human biopsy fibrosis reversal.", "confounders_present": [ "Combination components and noninvasive endpoints cannot establish lifestyle or human biopsy fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 31, "pmid": "38112484", "title": "Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis.", "citation": "Ratziu V, Francque S, Behling CA et al. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2024.", "doi": "10.1097/HEP.0000000000000723", "pmcid": "PMC11185915", "url": "https://pubmed.ncbi.nlm.nih.gov/38112484/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38112484/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SEMA-DAILY-NCT02970942", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "AI reassessment of the semaglutide biopsy trial detected continuous histologic signals beyond categorical endpoints.", "what_it_does_not_show": "Shares the original daily semaglutide parent; a posthoc continuous-image measure does not overturn its prespecified categorical fibrosis null or supply a new causal study.", "confounders_present": [ "Shares the original daily semaglutide parent; a posthoc continuous-image measure does not overturn its prespecified categorical fibrosis null or supply a new causal study." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 32, "pmid": "38324483", "title": "A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.", "citation": "Harrison SA, Bedossa P, Guy CD et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2309000", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38324483/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38324483/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MAESTRO-NASH found greater 52-week MASH resolution and fibrosis improvement with resmetirom than placebo in 966 participants.", "what_it_does_not_show": "A liver-directed drug establishes its own biopsy efficacy rather than assigned lifestyle efficacy or hard clinical-event prevention.", "confounders_present": [ "A liver-directed drug establishes its own biopsy efficacy rather than assigned lifestyle efficacy or hard clinical-event prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 33, "pmid": "38856224", "title": "Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.", "citation": "Loomba R, Hartman ML, Lawitz EJ et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine. 2024.", "doi": "10.1056/NEJMoa2401943", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38856224/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38856224/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "Erratum In: PMID41880634" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SYNERGY-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SYNERGY-NASH randomized 190 participants and found greater 52-week MASH resolution and fibrosis improvement with tirzepatide, using its missing-biopsy analysis.", "what_it_does_not_show": "Drug action is distinct; 157 had follow-up biopsies and an indexed erratum remains linked, whose correction details have not been separately examined.", "confounders_present": [ "Drug action is distinct; 157 had follow-up biopsies and an indexed erratum remains linked, whose correction details have not been separately examined." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 34, "pmid": "26608256", "title": "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.", "citation": "Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England). 2016.", "doi": "10.1016/S0140-6736(15)00803-X", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/26608256/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26608256/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "LEAN", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "LEAN found greater 48-week NASH resolution and less fibrosis progression with liraglutide in a small randomized paired-biopsy trial.", "what_it_does_not_show": "Only 45 of 52 had endpoint biopsies; drug and lifestyle mediators are not separated, and less progression is not universal fibrosis reversal.", "confounders_present": [ "Only 45 of 52 had endpoint biopsies; drug and lifestyle mediators are not separated, and less progression is not universal fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 35, "pmid": "34670042", "title": "A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.", "citation": "Francque SM, Bedossa P, Ratziu V et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. The New England journal of medicine. 2021.", "doi": "10.1056/NEJMoa2036205", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/34670042/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34670042/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34670042", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "NATIVE found positive activity and selected resolution/fibrosis endpoints with high-dose lanifibranor over 24 weeks despite weight gain.", "what_it_does_not_show": "Lower-dose primary significance differed; the result challenges weight-loss necessity for every therapy without refuting lifestyle sufficiency.", "confounders_present": [ "Lower-dose primary significance differed; the result challenges weight-loss necessity for every therapy without refuting lifestyle sufficiency." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 36, "pmid": "31727409", "title": "Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.", "citation": "Harrison SA, Bashir MR, Guy CD et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England). 2019.", "doi": "10.1016/S0140-6736(19)32517-6", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31727409/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31727409/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RESMET-PHASE2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "The randomized phase-2 resmetirom trial reduced its MRI-fat primary endpoint over 36 weeks in biopsy-confirmed NASH.", "what_it_does_not_show": "The examined abstract does not supply complete secondary biopsy-component evidence; MRI response is not hard-event prevention or isolated weight mediation.", "confounders_present": [ "The examined abstract does not supply complete secondary biopsy-component evidence; MRI response is not hard-event prevention or isolated weight mediation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 37, "pmid": "39970876", "title": "Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study.", "citation": "Song Y, Ni W, Zheng M et al. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell reports. Medicine. 2025.", "doi": "10.1016/j.xcrm.2025.101939", "pmcid": "PMC11866479", "url": "https://pubmed.ncbi.nlm.nih.gov/39970876/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39970876/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39970876", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A 124-person biopsy-MASH trial reported better histologic improvement with vitamin E 300 mg than placebo.", "what_it_does_not_show": "Drug-specific benefit does not prove assigned lifestyle efficacy, and the abstract does not specify enough timing/component detail to reconstruct every registered histology criterion.", "confounders_present": [ "Drug-specific benefit does not prove assigned lifestyle efficacy, and the abstract does not specify enough timing/component detail to reconstruct every registered histology criterion." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 38, "pmid": "31813633", "title": "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.", "citation": "Younossi ZM, Ratziu V, Loomba R et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2019.", "doi": "10.1016/S0140-6736(19)33041-7", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/31813633/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31813633/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "Erratum In: PMID32738952", "Erratum In: PMID34147150" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REGENERATE", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "REGENERATE reported a positive 18-month fibrosis endpoint with higher-dose obeticholic acid while NASH-resolution endpoints were nonsignificant.", "what_it_does_not_show": "Fibrosis and active steatohepatitis can dissociate; indexed errata remain attached and their details were not independently audited; pruritus and clinical-event uncertainty matter.", "confounders_present": [ "Fibrosis and active steatohepatitis can dissociate; indexed errata remain attached and their details were not independently audited; pruritus and clinical-event uncertainty matter." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 39, "pmid": "27322798", "title": "Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.", "citation": "Cusi K, Orsak B, Bril F et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Annals of internal medicine. 2016.", "doi": "10.7326/M15-1774", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/27322798/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27322798/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27322798", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Pioglitazone versus placebo on matched hypocaloric diet improved NASH histology in 101 prediabetic/diabetic adults over 18 months despite weight gain.", "what_it_does_not_show": "The randomized addition is pioglitazone, not diet; weight gain counters universal weight-loss necessity without erasing lifestyle efficacy.", "confounders_present": [ "The randomized addition is pioglitazone, not diet; weight gain counters universal weight-loss necessity without erasing lifestyle efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 40, "pmid": "40980971", "title": "Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes.", "citation": "Henney AE, Riley DR, Anson M et al. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver international : official journal of the International Association for the Study of the Liver. 2025.", "doi": "10.1111/liv.70367", "pmcid": "PMC12452214", "url": "https://pubmed.ncbi.nlm.nih.gov/40980971/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40980971/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40980971", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A target-trial emulation associated some GLP1-based therapies with fewer major adverse liver outcomes over two years, with drug-specific differences.", "what_it_does_not_show": "EHR confounding and exposure/diagnosis ascertainment remain; it is not an actual randomized event trial or lifestyle-to-event mediation test.", "confounders_present": [ "EHR confounding and exposure/diagnosis ascertainment remain; it is not an actual randomized event trial or lifestyle-to-event mediation test." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 41, "pmid": "41066427", "title": "Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide.", "citation": "Caussy C, Cusi K, Rosenstock J et al. Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. Diabetes care. 2025.", "doi": "10.2337/dc25-1306", "pmcid": "PMC12635880", "url": "https://pubmed.ncbi.nlm.nih.gov/41066427/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41066427/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SYNERGY-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "SYNERGY-NASH posthoc responder and mediation analyses associated achieved weight/metabolic changes with biopsy response.", "what_it_does_not_show": "Shares the parent trial and uses completers/responders; statistical mediation does not randomize weight or establish a necessary isolated mediator.", "confounders_present": [ "Shares the parent trial and uses completers/responders; statistical mediation does not randomize weight or establish a necessary isolated mediator." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 42, "pmid": "42527732", "title": "Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset.", "citation": "Mironova M, Padmanabhan K, Schneider D et al. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics. 2026.", "doi": "10.1111/apt.70888", "pmcid": "PMC13559488", "url": "https://pubmed.ncbi.nlm.nih.gov/42527732/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42527732/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A MAESTRO-NASH F2-F3 analysis reports stage-defined histologic benefits of resmetirom.", "what_it_does_not_show": "Baseline stage is valid context but the participants share the primary parent and do not create an independent lifestyle or drug causal line.", "confounders_present": [ "Baseline stage is valid context but the participants share the primary parent and do not create an independent lifestyle or drug causal line." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 43, "pmid": "29333665", "title": "Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.", "citation": "Hameed B, Terrault NA, Gill RM et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2018.", "doi": "10.1111/apt.14492", "pmcid": "PMC5931362", "url": "https://pubmed.ncbi.nlm.nih.gov/29333665/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29333665/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "FLINT-NCT01265498", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "mixed", "what_it_shows": "FLINT posthoc analysis associated weight change with additive histology responses during obeticholic-acid treatment, with adverse metabolic changes.", "what_it_does_not_show": "This is a different OCA parent from REGENERATE; achieved weight is nonrandomized and does not isolate lifestyle causality or weight necessity.", "confounders_present": [ "This is a different OCA parent from REGENERATE; achieved weight is nonrandomized and does not isolate lifestyle causality or weight necessity." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 44, "pmid": "36508737", "title": "Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial.", "citation": "Hansen CD, Gram-Kampmann EM, Hansen JK et al. Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial. Annals of internal medicine. 2023.", "doi": "10.7326/M22-1787", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/36508737/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36508737/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36508737", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "A 165-person six-month LCHF versus HCLF diabetes trial improved weight and glycemia more with LCHF but found no between-group liver-biopsy NAFLD difference.", "what_it_does_not_show": "Not restricted to baseline MASH and no intentional weight-loss assignment; metabolic or weight improvement is not automatic histologic reversal, and benefits waned after diet discontinuation.", "confounders_present": [ "Not restricted to baseline MASH and no intentional weight-loss assignment; metabolic or weight improvement is not automatic histologic reversal, and benefits waned after diet discontinuation." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 45, "pmid": "23485520", "title": "The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.", "citation": "Ryan MC, Itsiopoulos C, Thodis T et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of hepatology. 2013.", "doi": "10.1016/j.jhep.2013.02.012", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/23485520/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23485520/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23485520", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A small biopsy-NAFLD crossover found Mediterranean-diet MRI-fat and insulin-sensitivity improvement without different weight loss.", "what_it_does_not_show": "Six-week periods and fat endpoints do not satisfy 24-week paired MASH histology; diet composition may act separately from weight change.", "confounders_present": [ "Six-week periods and fat endpoints do not satisfy 24-week paired MASH histology; diet composition may act separately from weight change." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 46, "pmid": "38914313", "title": "Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH.", "citation": "Mucinski JM, Salvador AF, Moore MP et al. Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH. Journal of hepatology. 2024.", "doi": "10.1016/j.jhep.2024.06.017", "pmcid": "PMC12007730", "url": "https://pubmed.ncbi.nlm.nih.gov/38914313/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38914313/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT03151798", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS and METHODS:paragraph0, 1:MATERIALS and METHODS:paragraph1, 1:MATERIALS and METHODS:paragraph4, 2:RESULTS:paragraph0, 2:RESULTS:paragraph1, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "A small randomized ten-month energy-restriction/HIIT trial reported treatment improvements in inflammation, ballooning and steatohepatitis, while mean fibrosis remained unchanged.", "what_it_does_not_show": "Actual Methods/Results define clinical histologic resolution; Results report 9 treatment and 0 control resolutions (final sample 16 and 8), reconcilable with eight treated ballooning-to-0 reductions because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm without a printed between-group test, controls entered with higher MRS liver fat (24% versus 15%), and bundled treatment and correlational mediators preclude isolated weight causality.", "confounders_present": [ "Actual Methods/Results define clinical histologic resolution; Results report 9 treatment and 0 control resolutions (final sample 16 and 8), reconcilable with eight treated ballooning-to-0 reductions because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm without a printed between-group test, controls entered with higher MRS liver fat (24% versus 15%), and bundled treatment and correlational mediators preclude isolated weight causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] }, { "n": 47, "pmid": "35538056", "title": "A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease.", "citation": "Cheng R, Wang L, Le S et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease. Nature communications. 2022.", "doi": "10.1038/s41467-022-29968-0", "pmcid": "PMC9091228", "url": "https://pubmed.ncbi.nlm.nih.gov/35538056/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35538056/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35538056", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A four-arm diet/exercise NAFLD-prediabetes trial linked liver-fat and microbiome changes in 85 of 115 completers over about nine months.", "what_it_does_not_show": "No actual follow-up MASH histology or randomized microbial mediator; completer associations cannot establish microbiome necessity or fibrosis reversal.", "confounders_present": [ "No actual follow-up MASH histology or randomized microbial mediator; completer associations cannot establish microbiome necessity or fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 48, "pmid": "38035997", "title": "Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial.", "citation": "Chooi YC, Zhang QA, Magkos F et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. The American journal of clinical nutrition. 2024.", "doi": "10.1016/j.ajcnut.2023.11.013", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/38035997/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38035997/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38035997", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "TANGO compared diet strategies in 88 Chinese women and found short-term fat/weight responses.", "what_it_does_not_show": "Twelve-week noninvasive outcomes and restricted sex/context do not establish the registered adult MASH histology response.", "confounders_present": [ "Twelve-week noninvasive outcomes and restricted sex/context do not establish the registered adult MASH histology response." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 49, "pmid": "33042004", "title": "Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity.", "citation": "Cunha GM, Guzman G, Correa De Mello LL et al. Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity. Frontiers in endocrinology. 2020.", "doi": "10.3389/fendo.2020.00607", "pmcid": "PMC7521128", "url": "https://pubmed.ncbi.nlm.nih.gov/33042004/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33042004/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33042004", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A 39-person two-month very-low-calorie ketogenic diet study reduced MRI liver fat and weight.", "what_it_does_not_show": "Short exposure, noninvasive fat and different dietary composition cannot establish inflammation/ballooning or fibrosis reversal.", "confounders_present": [ "Short exposure, noninvasive fat and different dietary composition cannot establish inflammation/ballooning or fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 50, "pmid": "30667502", "title": "Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial.", "citation": "Schwimmer JB, Ugalde-Nicalo P, Welsh JA et al. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019.", "doi": "10.1001/jama.2018.20579", "pmcid": "PMC6440226", "url": "https://pubmed.ncbi.nlm.nih.gov/30667502/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30667502/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "Erratum In: PMID31386114" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30667502", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A 40-boy randomized free-sugar-restriction trial reduced liver fat over eight weeks in adolescent NAFLD.", "what_it_does_not_show": "Children, short follow-up and MRI-fat outcome are outside registered adult MASH biopsy scope; an indexed erratum remains linked rather than counted as an original study.", "confounders_present": [ "Children, short follow-up and MRI-fat outcome are outside registered adult MASH biopsy scope; an indexed erratum remains linked rather than counted as an original study." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 51, "pmid": "26394161", "title": "Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.", "citation": "Armstrong MJ, Hull D, Guo K et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of hepatology. 2016.", "doi": "10.1016/j.jhep.2015.08.038", "pmcid": "PMC4713865", "url": "https://pubmed.ncbi.nlm.nih.gov/26394161/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26394161/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "LEAN", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "LEAN's 14-person mechanism substudy examined clamp and cellular changes during 12 weeks of liraglutide.", "what_it_does_not_show": "Shares the LEAN treatment platform; physiological and cell findings do not establish isolated weight mediation, a new clinical histology line or the registered horizon.", "confounders_present": [ "Shares the LEAN treatment platform; physiological and cell findings do not establish isolated weight mediation, a new clinical histology line or the registered horizon." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 52, "pmid": "34558835", "title": "Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.", "citation": "Takahashi H, Kessoku T, Kawanaka M et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatology communications. 2022.", "doi": "10.1002/hep4.1696", "pmcid": "PMC8710792", "url": "https://pubmed.ncbi.nlm.nih.gov/34558835/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34558835/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34558835", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Ipragliflozin versus control in a small 72-week diabetes/NAFLD paired-biopsy trial reported more fibrosis improvement and NASH resolution.", "what_it_does_not_show": "A distinct drug in a mixed baseline NAFLD population is not a lifestyle causal comparison; incomplete follow-up biopsies and small numbers limit transfer.", "confounders_present": [ "A distinct drug in a mixed baseline NAFLD population is not a lifestyle causal comparison; incomplete follow-up biopsies and small numbers limit transfer." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 53, "pmid": "39250515", "title": "Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.", "citation": "Younossi ZM, Stepanova M, Racila A et al. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology (Baltimore, Md.). 2025.", "doi": "10.1097/HEP.0000000000001084", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39250515/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39250515/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MAESTRO-NASH reported health-related quality-of-life patterns related to histologic response.", "what_it_does_not_show": "Shares the parent and response-defined analysis; functional association does not establish liver-death prevention or independent efficacy.", "confounders_present": [ "Shares the parent and response-defined analysis; functional association does not establish liver-death prevention or independent efficacy." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 54, "pmid": "33860116", "title": "Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.", "citation": "Harrison SA, Bashir M, Moussa SE et al. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatology communications. 2021.", "doi": "10.1002/hep4.1657", "pmcid": "PMC8034581", "url": "https://pubmed.ncbi.nlm.nih.gov/33860116/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33860116/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RESMET-PHASE2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A small selected resmetirom extension documented continued noninvasive hepatic/metabolic responses out to 72 weeks.", "what_it_does_not_show": "An open-label completer extension shares its phase-2 parent, lacks concurrent randomized control and cannot establish lifestyle or event prevention.", "confounders_present": [ "An open-label completer extension shares its phase-2 parent, lacks concurrent randomized control and cannot establish lifestyle or event prevention." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 55, "pmid": "42765724", "title": "GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study.", "citation": "Koutouratsas T, Kalligeros M, Michael M et al. GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study. Age and ageing. 2026.", "doi": "10.1093/ageing/afag281", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/42765724/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42765724/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42765724", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "mixed", "what_it_shows": "A matched older-adult MASLD EHR cohort associated GLP1 initiation with lower decompensation and mortality hazards but no lower MACE hazard.", "what_it_does_not_show": "Coded diagnoses, residual prescribing confounding and varying follow-up remain; drug associations cannot prove lifestyle or surrogate-to-clinical causality.", "confounders_present": [ "Coded diagnoses, residual prescribing confounding and varying follow-up remain; drug associations cannot prove lifestyle or surrogate-to-clinical causality." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 56, "pmid": "41113119", "title": "Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.", "citation": "Browne SK, Suschak JJ, Tomah S et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP reports : innovation in hepatology. 2025.", "doi": "10.1016/j.jhepr.2025.101483", "pmcid": "PMC12529369", "url": "https://pubmed.ncbi.nlm.nih.gov/41113119/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41113119/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41113119", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "A 64-person pemvidutide extension retained assigned doses and showed greater MRI-fat and weight reductions at 24 weeks.", "what_it_does_not_show": "Selected extension completers and imaging endpoints do not establish paired-biopsy MASH/fibrosis or isolate weight versus direct glucagon action.", "confounders_present": [ "Selected extension completers and imaging endpoints do not establish paired-biopsy MASH/fibrosis or isolate weight versus direct glucagon action." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [] }, { "n": 57, "pmid": "37845512", "title": "Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.", "citation": "Harrison SA, Taub R, Neff GW et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine. 2023.", "doi": "10.1038/s41591-023-02603-1", "pmcid": "PMC10667098", "url": "https://pubmed.ncbi.nlm.nih.gov/37845512/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37845512/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NAFLD1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "MAESTRO-NAFLD-1 randomized resmetirom in presumed NASH and documented safety plus MRI-fat/lipid/stiffness responses over 52 weeks.", "what_it_does_not_show": "Different trial from biopsy MAESTRO-NASH; presumed disease and noninvasive endpoints cannot independently prove MASH histologic reversal.", "confounders_present": [ "Different trial from biopsy MAESTRO-NASH; presumed disease and noninvasive endpoints cannot independently prove MASH histologic reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 58, "pmid": "39824443", "title": "Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD.", "citation": "Barb D, Kalavalapalli S, Godinez Leiva E et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of hepatology. 2025.", "doi": "10.1016/j.jhep.2024.12.045", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/39824443/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39824443/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39824443", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2" ], "favors_models": [], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Lanifibranor in 38 diabetes/MASLD adults improved hepatic fat and clamp insulin sensitivity over 24 weeks despite modest weight gain.", "what_it_does_not_show": "A different metabolic trial lacks the registered paired-biopsy MASH endpoint; positive fat/glycemia cannot be promoted to fibrosis or hard liver events.", "confounders_present": [ "A different metabolic trial lacks the registered paired-biopsy MASH endpoint; positive fat/glycemia cannot be promoted to fibrosis or hard liver events." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 59, "pmid": "33655500", "title": "Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.", "citation": "Kannt A, Wohlfart P, Madsen AN et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. British journal of pharmacology. 2021.", "doi": "10.1111/bph.15427", "pmcid": "", "url": "https://pubmed.ncbi.nlm.nih.gov/33655500/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33655500/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33655500", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Moderate", "system": "animal", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Resmetirom in biopsy-confirmed diet-induced mouse NASH improved fat/activity and fibrogenic measures without changing weight.", "what_it_does_not_show": "Forced diet/model exposure and liver-directed drug do not establish endogenous human weight mechanisms or assigned lifestyle response; alpha-SMA/gene changes are not universal clinical fibrosis proof.", "confounders_present": [ "Forced diet/model exposure and liver-directed drug do not establish endogenous human weight mechanisms or assigned lifestyle response; alpha-SMA/gene changes are not universal clinical fibrosis proof." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "", "shared_components": [] }, { "n": 60, "pmid": "32239376", "title": "Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease.", "citation": "Stine JG, Xu D, Schmitz K et al. Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. Digestive diseases and sciences. 2020.", "doi": "10.1007/s10620-020-06226-1", "pmcid": "PMC7529701", "url": "https://pubmed.ncbi.nlm.nih.gov/32239376/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32239376/", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32239376", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Three biopsy-NASH patients showed lower hepatic rpS6 phosphorylation after a 20-week exercise intervention.", "what_it_does_not_show": "Uncontrolled tiny marker study is below the registered duration and does not establish pathway necessity, MASH resolution or actual fibrosis reversal.", "confounders_present": [ "Uncontrolled tiny marker study is below the registered duration and does not establish pathway necessity, MASH resolution or actual fibrosis reversal." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": false, "decisive_test_note": "", "shared_components": [ "EXERCISE-20WK-PARENT-UNRESOLVED" ] }, { "n": 61, "pmid": "23814606", "title": "Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.", "citation": "Eckard C, Cole R, Lockwood J et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic advances in gastroenterology. 2013.", "doi": "10.1177/1756283X13484078", "pmcid": "PMC3667474", "url": "https://pubmed.ncbi.nlm.nih.gov/23814606/", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23814606/", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-11-02", "status_checked_on": "2026-11-02", "study_id": "PMID23814606", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and record metadata examined during the 2026-11-02 adversarial pass (added on that pass's finding WL-2); no complete-paper or supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "mixed", "what_it_shows": "Eckard et al. 2013 randomized 56 adults with biopsy-proven NAFLD to standard care or one of three diet/exercise arms for six months with repeat biopsy; NAS improved in the 41 completers (88% with NASH) as a whole (p < 0.001) with no difference between arms, standard care included (p = 0.31).", "what_it_does_not_show": "A randomized lifestyle-versus-standard-care paired-biopsy contrast was null; mixed NAFLD/NASH entry, completer analysis and small arms limit it, NAS is a composite rather than current resolution criteria, and it does not refute the positive SC2 trial.", "confounders_present": [ "A randomized lifestyle-versus-standard-care paired-biopsy contrast was null; mixed NAFLD/NASH entry, completer analysis and small arms limit it, NAS is a composite rather than current resolution criteria, and it does not refute the positive SC2 trial." ], "verification": "verified", "verification_note": "Bounded source attribution; not proof of the nominal mechanism. Added by adversarial finding WL-2 (Claude Opus 5.5, 2026-11-02) after PubMed record verification.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "discriminating_contrast": true, "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.", "shared_components": [] } ], "verification_summary": { "load_bearing_claims_checked": 66, "verified": 66, "unverified": 0, "contradicted": 0, "note": "Verified attribution is distinct from mechanism truth or complete body access." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.", "specific_trigger": "Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Perturbation in a defined setting versus broader inference", "subclaim_scope_cap_binds_on": "Lifestyle-mediated weight loss reverses steatohepatitis in adults with baseline biopsy-confirmed MASH.", "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope", "resolution": "A true clinical human pathology perturbation crosses Δ for its assigned lifestyle scope under the stated clinical adaptation. Universal biomarker cap 4 blocks MRI/ALT-to-histology and histology-to-hard-event inference, not the measured pathology response itself. Universal association cap 2 binds achieved-loss cohorts as isolated causal evidence, but is not re-applied to erase randomized package evidence. Different drug/surgery successes retain their own exposure and cannot be combined as independent lifestyle mediator proof.", "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID19827166", "gamma_hard_rules_triggered": [ "Direct biopsy pathological-component change is retained within SC1; fat is not promoted to the other outcomes." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Assigned lifestyle in the Promrat paired-biopsy trial reduced steatosis relative to education, and controlled exercise/metabolic work supports direct hepatic-fat change. This is a pathological fat component crossing within its measured scope, not a substitution of fat for steatohepatitis or hard-event benefit. The disease-stage and mediator boundaries prevent high-ladder generalization.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID38914313", "gamma_hard_rules_triggered": [ "Actual inflammation/ballooning clinical pathology is beyond marker-only evidence; broad transfer and weight mediation remain unproven." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "The newer randomized energy-restriction/HIIT trial explicitly defines histologic resolution by inflammation 0–1 and ballooning 0, and reports improvements in these components and steatohepatitis relative to its control trajectory at about ten months. This supplies a first direct assigned clinical phenotype perturbation. Its Results report resolution in 9 treatment and 0 control participants (final sample 16 and 8); the eight treated participants who reduced ballooning to 0 are compatible with nine resolutions because entry required NAS of at least 4, not ballooning of at least 1. Its small final sample, within-arm component reporting without a printed between-group test, and higher baseline MRS liver fat in controls (24% versus 15%) constrain confidence. Promrat improves a composite NAS and steatosis but has nonsignificant assigned component differences, so it reinforces activity change without being counted as a second current-resolution confirmation. The other randomized standard-care-controlled paired-biopsy lifestyle trial found on targeted search (Eckard 2013) showed improvement in every arm without a between-arm difference, so the assigned-package effect is not yet consistently reproduced. Broader clinical contexts and isolated weight mediation remain unestablished.", "ceiling_from_boundary_check": "Δ or higher" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "No significant assigned average lifestyle fibrosis improvement in the examined trial bodies." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension\n- Must separate developmental effects from true aging effects\n- Biomarker change alone does NOT satisfy this threshold", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "", "gamma_hard_rules_triggered": [ "Biomarker and surrogate effects are not hard hepatic events." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped.", "ceiling_from_boundary_check": "Γ" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[1] A 31-person randomized 48-week lifestyle-versus-education trial improved weight, NAS and steatosis; assigned inflammation/ballooning differences were nonsignificant and fibrosis unchanged." ], "what_would_cross_it": "" }, { "subclaim_id": "SC1", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "no", "supporting_evidence": [ "[1] A 31-person randomized 48-week lifestyle-versus-education trial improved weight, NAS and steatosis; assigned inflammation/ballooning differences were nonsignificant and fibrosis unchanged." ], "what_would_cross_it": "Replicate fat-component effects across prospectively enrolled stages and diet/exercise contrasts; mechanistically separate weight, composition and activity without borrowing downstream outcomes." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "yes", "supporting_evidence": [ "[46] A small randomized ten-month energy-restriction/HIIT trial reported treatment improvements in inflammation, ballooning and steatohepatitis, while mean fibrosis remained unchanged." ], "what_would_cross_it": "" }, { "subclaim_id": "SC2", "threshold": "Ε", "requirement_quoted": "Requires causal effect in constrained contexts, backgrounds, or species.", "satisfied": "no", "supporting_evidence": [ "[46] A small randomized ten-month energy-restriction/HIIT trial reported treatment improvements in inflammation, ballooning and steatohepatitis, while mean fibrosis remained unchanged." ], "what_would_cross_it": "Replicate predefined inflammation/ballooning resolution in adequately powered baseline-defined MASH cohorts and independently verify pathology, component estimates, attrition and safety. Map context before outcome and separate the weight mediator from the assigned package." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Obtain a sufficiently powered concurrent-control paired-biopsy lifestyle fibrosis result, with prespecified baseline stage, independent blinded readers and missing-biopsy estimands." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "Follow randomized or rigorously convergent assigned lifestyle exposures for adjudicated cirrhosis, decompensation and liver-related death; demonstrate and validate surrogate mediation rather than assume it." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Promrat assigned inflammation/ballooning contrasts nonsignificant and average fibrosis unchanged.", "New lifestyle trial average fibrosis unchanged despite histologic activity benefit.", "Weight-maintained exercise changes MRI fat without verified histologic/fibrotic benefit.", "Sham-controlled ESG increases weight loss but between-group NAS/fibrosis null.", "Compensated F4 semaglutide reduces weight/MRI fat but biopsy endpoints null.", "LCHF metabolic improvement without between-group biopsy difference.", "Lanifibranor/pioglitazone clinical pathology positives despite weight gain challenge weight-loss necessity across therapies." ], "note": "Outcome, exposure and stage boundaries are examined, but direct lifestyle resolution evidence is small and does not establish transfer across every diabetes, BMI or fibrosis-stage stratum. The baseline biopsy/age/assigned-treatment requirements were fixed before results. Achieved-at-least-7%/10% groups are reported associations, never used to exclude treatment failures from the primary scope." }, "falsification_patterns_met": [ { "pattern": "Fat and active/fibrotic disease dissociate", "evidence": "Multiple randomized comparator studies and actual lifestyle bodies show component nulls despite fat/weight improvement. This bounds inference without a second penalty.", "downgrade_applied": false }, { "pattern": "Weight loss is not necessary for every successful MASH therapy", "evidence": "Lanifibranor and pioglitazone pathology improvements despite weight gain. This refutes universal necessity, which was not the registered lifestyle-sufficiency claim.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "pitfall": "Composite endpoint substitution", "where": "NAS/steatosis is not automatically current inflammation/ballooning-defined MASH resolution." }, { "pitfall": "Scope fitted to outcome", "where": "Achieved-loss and responder subsets do not replace the assigned baseline-defined estimand." }, { "pitfall": "Therapeutic response treated as mechanism proof", "where": "Randomized package benefit does not isolate weight, exercise, diet composition or insulin sensitivity mediation." }, { "pitfall": "Surrogate promoted to hard outcome", "where": "MRI fat, ALT, stiffness and even activity biopsy change do not alone prove liver-death prevention." }, { "pitfall": "Replication confused with independence", "where": "Shared cohorts, secondary analyses, AI regrading and extensions remain their parent study." }, { "pitfall": "Unchecked numerical reconstruction", "where": "New lifestyle Results give nine treatment resolutions and eight treated ballooning-to-0 reductions; these reconcile because entry required NAS of at least 4 rather than ballooning of at least 1, and no resolution fraction is reconstructed beyond the paper's own figures (9 of 16 against 0 of 8; 56% in the Discussion)." } ], "causal_tally_audit": { "tally_claimed_by_document": 2, "tally_after_audit": 2, "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.", "screened_discriminating_contrasts": 34, "items_rejected": [ "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.", "One exact current-component primary clinical positive unit; older NAS trial is complementary activity evidence, not a second current-resolution study.", "The Vilar prediction/renal follow-ups, LEAN/SYNERGY/MAESTRO secondary reports and semaglutide AI reassessment do not add parent units.", "Positive drug/surgery endpoints, imaging thresholds and achieved-loss responder analyses do not count as assigned lifestyle mediator crossings." ] }, "steelman": { "case_one_rung_higher": "Ε could be defended by combining the two randomized lifestyle studies and calling their baseline MASH populations a mapped constrained context. The strongest objection is that the older composite response does not confirm the newer current-resolution components, and the small newer trial reports its component changes within arm, without a printed between-group test and with higher baseline liver fat in controls; the other randomized standard-care-controlled paired-biopsy lifestyle trial (Eckard 2013) found no between-arm difference. Prospective replication of the same clinical phenotype with clear component estimates and stage boundaries is needed.", "case_one_rung_lower": "Γ could be defended from fat-only NAS changes and achieved-loss associations. That position accurately bounds the older trial and cohorts but would ignore the actual newer randomized trial with explicit inflammation/ballooning histology and a reported resolution positive. These are measured disease pathology, not solely blood/imaging markers.", "which_rejected": "Retain Δ rather than Γ because a direct assigned package changes the registered clinical pathology. Retain Δ rather than Ε because the specific clinical-resolution confirmation, adequate context map and mechanistic mediator remain incomplete; one broad NAS trial plus one small current-resolution trial are not a high-ladder convergent set. Fibrosis/event uncertainty is kept separate rather than downgrading the primary twice.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up." }, "final_score": { "hsef_level": "Δ", "hsef_descriptor": "First field-valid causal perturbation crossed", "confidence": "Moderate", "confidence_rationale": "61 primary reports examined. Moderate rests on evidence density and reproducibility, not on reading access: a single small randomized trial supplies the only current-resolution positive and is unreplicated, its component changes are reported within arm with higher baseline liver fat in controls, the other randomized standard-care-controlled paired-biopsy lifestyle trial (Eckard 2013) found improvement in every arm without a between-arm difference, the older trial's assigned inflammation/ballooning contrasts are nonsignificant, and packages, comparators and histology definitions are heterogeneous. Confidence bounds the evidence base, not correctness.", "rests_on_non_peer_reviewed_work": false, "rationale": "The registered primary SC2 reaches Δ with Moderate confidence: a small randomized lifestyle package changes explicit steatohepatitis histology, while the older trial offers broader activity support. Direct original-body examination prevents calling fat-only NAS changes full resolution. Evidence does not yet map sufficiently broad baseline contexts or isolate achieved weight as the causal mediator to reach Ε or mechanistically narrowed convergence. Separate Γ fibrosis and surrogate-to-event companions do not erase the positive registered clinical phenotype." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": 5, "derivation": "Assigned lifestyle precedes improvement in established disease, so the intervention contributes to modifying or maintaining the metabolic disease trajectory. Engaging/removing a specific weight mediator has not established initiation, necessity and rate limitation. This coarse role describes metabolic contribution rather than declaring weight loss a primary disease driver; a therapeutic response does not determine endogenous causal primacy.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Mechanistic only", "artifact": "Completed contemporary lifestyle histology, incretin and liver-directed trials refine component and stage responses. ESSENCE has a registered longer 240-week clinical phase, but it is a drug trial and not a pending named lifestyle-primary result. No named pending exact lifestyle component-resolution result was verified in this bounded review.", "justification": "Completed contemporary lifestyle histology, incretin and liver-directed trials refine component and stage responses. ESSENCE has a registered longer 240-week clinical phase, but it is a drug trial and not a pending named lifestyle-primary result. No named pending exact lifestyle component-resolution result was verified in this bounded review." }, "stability": { "value": "Stable", "trigger": "The first positive clinical package evidence is established but small; no verified named pending exact lifestyle trial was identified. The newer trial's between-group component statistics and baseline liver-fat imbalance warrant clarification, while a proposed future study is not a named stability trigger.", "justification": "The first positive clinical package evidence is established but small; no verified named pending exact lifestyle trial was identified. The newer trial's between-group component statistics and baseline liver-fat imbalance warrant clarification, while a proposed future study is not a named stability trigger." }, "divergence": { "implied_level": null, "implied_level_basis": "Clinical lifestyle advice, achieved-loss targets and commercial reversal claims imply different propositions; no measured single field ladder level.", "assessed_level": "Δ", "gap_in_rungs": null, "value": "Contested", "justification": "Do not manufacture a consensus or arithmetic evidence-belief gap from traffic ranking or provider wording." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "none assigned", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": true, "new_level": "Δ", "direction": "newly assigned", "what_moved_it": "Fresh primary evidence appraisal; not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Registered boundary experiment", "experiment": "A multicentre lifestyle-versus-matched-support randomized trial enrolls baseline-biopsy MASH adults, stratifies fibrosis stage and diabetes before outcomes, and measures independently read paired inflammation/ballooning resolution at 52–104 weeks. Factorial diet/exercise and prospectively controlled energy/weight trajectories distinguish package efficacy from isolated mediator claims; retain all assigned participants and specify missing-biopsy sensitivity analyses. Extend blinded hepatic event follow-up.", "readout": "Actual inflammation/ballooning histology, paired fibrosis and adverse events; MRI/ALT and weight are secondary. Long-term adjudicated decompensation/cirrhosis/liver-related death are separate endpoints.", "critical_control": "Matched support and medication stability, blinded independent pathology readers, prespecified stage/diabetes interaction tests, full-population assignment estimands, component counts reconciled and multiplicity addressed.", "supporting_result": "Replicated positive current-resolution differences with consistent blinded component estimates and baseline context interactions justify a higher clinical rung; controlled fibrosis/event positives must satisfy their separate claims.", "falsifying_result": "Fat-only changes without inflammation/ballooning benefit leave current-resolution unconfirmed in that context; full-population nulls cannot be rescued by selecting achieved-loss responders." } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Independent adequately powered current-resolution replication of assigned lifestyle in baseline MASH.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 2", "statement": "Baseline ballooning distribution and a printed between-group resolution test for PMID38914313.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 3", "statement": "Isolated weight versus activity, diet composition and peripheral metabolic mediation.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 4", "statement": "Prospective stage/diabetes interaction mapping and paired-biopsy missingness sensitivity.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 5", "statement": "Controlled lifestyle fibrosis improvement and durability beyond active histology response.", "relevance": "Limits mechanism identification or scope." }, { "name": "Gap 6", "statement": "Hard hepatic events and harms beyond short selected cohorts; full supplements and all complete papers remain unaudited.", "relevance": "Limits mechanism identification or scope." } ], "review_metadata": { "review_date": "2026-10-13", "reviewer": "Codex", "evidence_base_note": "61 primary reports (PMID23814606 added from its PubMed record on the 2026-11-02 adversarial pass); literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.", "skill_version": "5.3", "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.", "validator_warnings_addressed": "No warnings.", "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs.", "adversarial_review": { "reviewer": "Claude Opus 5.5 (Anthropic)", "date": "2026-11-02", "pass": "second independent adversarial pass (first pass 2026-10-14, WM-1 to WM-5)", "findings_applied": [ "WL-1", "WL-2", "WL-3", "WL-4", "WL-5", "WL-6", "WL-7", "WL-8" ], "level_after": "Δ", "confidence_after": "Moderate", "records": [ "ADVERSARIAL_REVIEW.weight-loss-mash-reversal.md", "adversarial-findings.weight-loss-mash-reversal.json", "validation-round3-2026-11-02.json" ] } }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Assigned clinical treatment is available and supplies Δ. Adequate prospective context replication, a randomized or credible orthogonal weight-mediator test, and longer event evidence could move the claim upward. Drug classes, mouse THR-beta action and achieved-weight dose gradients concern different exposures or confounders; no set presently excludes shared lifestyle adherence, cointervention and small-study pathology failure modes for the exact primary. Human genetics and lifelong natural experiments were considered but no qualifying exact-exposure clinical set was examined." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "Assigned clinical treatment is available and supplies Δ. Adequate prospective context replication, a randomized or credible orthogonal weight-mediator test, and longer event evidence could move the claim upward. Drug classes, mouse THR-beta action and achieved-weight dose gradients concern different exposures or confounders; no set presently excludes shared lifestyle adherence, cointervention and small-study pathology failure modes for the exact primary. Human genetics and lifelong natural experiments were considered but no qualifying exact-exposure clinical set was examined." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Assigned clinical treatment is available and supplies Δ. Adequate prospective context replication, a randomized or credible orthogonal weight-mediator test, and longer event evidence could move the claim upward. Drug classes, mouse THR-beta action and achieved-weight dose gradients concern different exposures or confounders; no set presently excludes shared lifestyle adherence, cointervention and small-study pathology failure modes for the exact primary. Human genetics and lifelong natural experiments were considered but no qualifying exact-exposure clinical set was examined." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Assigned clinical treatment is available and supplies Δ. Adequate prospective context replication, a randomized or credible orthogonal weight-mediator test, and longer event evidence could move the claim upward. Drug classes, mouse THR-beta action and achieved-weight dose gradients concern different exposures or confounders; no set presently excludes shared lifestyle adherence, cointervention and small-study pathology failure modes for the exact primary. Human genetics and lifelong natural experiments were considered but no qualifying exact-exposure clinical set was examined." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": false, "why_not_sufficient": "Assigned clinical treatment is available and supplies Δ. Adequate prospective context replication, a randomized or credible orthogonal weight-mediator test, and longer event evidence could move the claim upward. Drug classes, mouse THR-beta action and achieved-weight dose gradients concern different exposures or confounders; no set presently excludes shared lifestyle adherence, cointervention and small-study pathology failure modes for the exact primary. Human genetics and lifelong natural experiments were considered but no qualifying exact-exposure clinical set was examined." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 61, "claims_total": 66, "claims_verified": 66, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 61, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "A 31-person randomized 48-week lifestyle-versus-education trial improved weight, NAS and steatosis; assigned inflammation/ballooning differences were nonsignificant and fibrosis unchanged. Actual Methods/Results use a composite NAS endpoint, not current resolution criteria; positive achieved-loss component strata are nonrandomized and cannot prove isolated weight mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph11, 0:Methods:paragraph13, 0:Methods:paragraph14, 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph9, 1:Results:paragraph12. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C2", "text": "Prospective 293-person lifestyle cohort with 261 paired biopsies found steatohepatitis resolution and fibrosis regression associated with greater achieved weight loss. Achieved at-least-10% subgroup is not a randomized treatment or baseline scope; no control and missing biopsies limit causal attribution and independence.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C3", "text": "A split development/validation analysis predicts histologic resolution using weight loss, metabolic status, ALT and baseline features. Shares the lifestyle cohort; posttreatment predictors and internal validation are not a new causal trial or proof of prevented clinical events.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C4", "text": "Shared lifestyle-cohort posthoc analysis associates histology improvement with eGFR change over 52 weeks. Renal correlation is not independent randomized evidence or cirrhosis/liver-death prevention; shared participants remain one study.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C5", "text": "Lifestyle-versus-education paired biopsies show weight-associated changes in ceramide expression/serum measures. Shares the primary lifestyle trial; molecular correlation is not ceramide necessity or an additional independent histology efficacy line.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C6", "text": "Exercise at maintained weight reduced hepatic triglyceride and visceral fat in 24 biopsy-confirmed NASH adults over 12 weeks, with inflammation/fibrosis markers unchanged. No repeated biopsy and below registered 24-week gate; liver-fat improvement cannot establish steatohepatitis or fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C7", "text": "Pooled exercise trials increased odds of a 30% MRI-fat reduction with little weight loss and improved fitness. The endpoint is an imaging surrogate, not measured histologic response or fibrosis improvement; pooled parents do not create independent clinical histology lines.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C8", "text": "Twelve-week HIIT in 23 NAFLD adults reduced liver fat and improved selected cardiac/body measures, with glucose-control nulls. No paired NASH histology and short follow-up; fat reduction does not imply ballooning/inflammation reversal or hard liver outcomes.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C9", "text": "Six-month Mediterranean diet/lifestyle counseling reduced weight and selected ALT/stiffness measures versus written advice. Ultrasound NAFLD and elastography are not biopsy-confirmed MASH resolution/fibrosis; bundled diet, exercise and sleep cannot isolate weight mediation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C10", "text": "Fasting-plus-exercise reduced liver fat versus exercise/control in an 80-person three-month trial, with several metabolic and fibrosis-score nulls. No biopsy MASH and short exposure; no clear added benefit over fasting alone, and scores cannot establish fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C11", "text": "An 18-month multidisciplinary MASLD trial improved adherence, weight and liver imaging/stiffness and reported fewer acute cardiovascular events. No paired MASH biopsy or hard hepatic endpoint is established from the abstract; cardiovascular events are distinct from cirrhosis/liver-death prevention and component mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3", "SC4" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C12", "text": "A 228-person diet/exercise trial found liver imaging/stiffness differences despite no between-group weight advantage. FibroScan improvements are not histologic fibrosis reversal; MRI NAFLD differs from registered biopsy-MASH and diet components may act independently of weight.", "carries_number": true, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C13", "text": "Twelve-person uncontrolled multidisciplinary program reduced weight, liver tests and noninvasive fat estimates over three months. No control, biopsy or registered horizon; association does not establish steatohepatitis reversal or clinical events.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C14", "text": "Viusid-plus-diet/exercise versus diet/exercise in 60 biopsy-NAFLD adults improved NAS more with supplement; both groups improved histology. Randomization isolates supplement addition rather than lifestyle efficacy; between-group fibrosis difference was nonsignificant, and shared cointerventions cannot prove weight necessity.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C15", "text": "Ten biopsy-NASH adults receiving orlistat plus dietary counseling showed observed weight/metabolic and selected paired-biopsy improvements over six months. Uncontrolled drug/lifestyle combination and achieved-loss subgroup cannot establish assigned lifestyle causality or universal fibrosis reversal.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C16", "text": "Balloon versus sham on matched diet/exercise lowered BMI and NAS in an 18-person six-month pilot. No inflammation, ballooning or fibrosis score change; a NAS difference cannot automatically be called full MASH resolution, and device addition is a distinct intervention.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C17", "text": "ESG versus sham with matched lifestyle in 40 biopsy-MASH adults increased loss and reduced steatosis/stiffness at 72 weeks. Between-group NAS and fibrosis were null; achieved-over-10% NAS subgroup is nonrandomized and does not rescue broad histology/fibrosis claims.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C18", "text": "MAESTRO secondary analysis associates achieved weight loss with larger resmetirom histology/imaging responses across selected diabetes-drug backgrounds. Shared primary trial and nonrandomized achieved weight/background treatment cannot isolate lifestyle mediation or add an independent drug causal line.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C19", "text": "Nine-month oligofructose pilot in 14 biopsy-NASH adults improved NAS/steatosis independent of weight loss. Steatosis-driven score change and small prebiotic exposure do not establish lifestyle-loss necessity or verified inflammation/ballooning reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C20", "text": "HTD1801 hamster biopsy benefit accompanies an original human secondary analysis showing MRI/serum response proxies in presumed MASH. Human histology was not measured; model results and predictive response criteria cannot establish patient MASH/fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C21", "text": "Curcumin-plus-lifestyle trial showed several within-group changes but no superiority for main metabolic/steatosis measures versus lifestyle-placebo. No paired biopsy or isolated lifestyle randomization; within-group fibrosis-score improvement is not a between-group clinical reversal effect.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C22", "text": "Silymarin/vitamin-E-plus-diet versus diet reduced selected noninvasive indices in baseline biopsy-NAFLD over three months. No follow-up biopsy and distinct exercise/supplement cointerventions; post-loss subgroup indices cannot establish fibrosis or histologic reversal.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C23", "text": "ESSENCE randomized semaglutide 2.4 mg weekly in biopsy-MASH; the first 800 at 72 weeks had greater histologic resolution and fibrosis improvement than placebo. Distinct drug exposure and interim histology do not establish lifestyle mediation or the ongoing 240-week clinical-event result; pain endpoint was null and GI events more common.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C24", "text": "In 71 compensated F4 patients, 48-week semaglutide reduced weight and MRI fat but did not significantly improve biopsy fibrosis, NASH resolution or component scores. Selected original Methods/Results confirm stage-specific dissociation; absence of decompensation in this small short trial is not prevention proof and biopsy availability differed by arm.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph10, 1:Methods:paragraph11, 1:Methods:paragraph15, 2:Results:paragraph5, 2:Results:paragraph8, 2:Results:paragraph9, 2:Results:paragraph11, 2:Results:paragraph15, 2:Results:paragraph24. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C25", "text": "A 320-person daily semaglutide biopsy trial found greater NASH resolution at the highest dose but a nonsignificant fibrosis endpoint at 72 weeks. Daily dosing and drug action differ from lifestyle; fibrosis null cannot be replaced by steatosis or posthoc continuous-image improvement.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C26", "text": "A prospective bariatric cohort found substantial observed NASH resolution and fibrosis regression in available five-year biopsies. Surgery is distinct from lifestyle, follow-up exceeds the registered primary horizon, and selective repeat biopsies without random control limit causal and hard-event inference.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3", "SC4" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C27", "text": "SPLENDOR associated bariatric surgery with lower long-term major adverse liver and cardiovascular events in biopsy-fibrotic NASH. Weighted observational surgery comparison is not randomized lifestyle-event evidence; raw and adjusted risk differences are different estimands, and perioperative deaths remain relevant.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C28", "text": "Semaglutide in an MRI-defined NAFLD trial reduced liver fat without a significant liver-stiffness benefit. MRI fat and stiffness are distinct from actual inflammation, ballooning and fibrosis biopsy; a drug trial does not isolate lifestyle or weight mediation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C29", "text": "BRAVES randomized 288 participants and found more one-year NASH resolution with either bariatric operation than lifestyle plus best medical care. The lifestyle-arm response rate lacks an untreated comparator; surgery and cointerventions differ, and operative serious adverse events cannot be omitted.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C30", "text": "A 24-week semaglutide combination trial improved selected MRI-fat and metabolic measures with additional experimental drugs. Combination components and noninvasive endpoints cannot establish lifestyle or human biopsy fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C31", "text": "AI reassessment of the semaglutide biopsy trial detected continuous histologic signals beyond categorical endpoints. Shares the original daily semaglutide parent; a posthoc continuous-image measure does not overturn its prespecified categorical fibrosis null or supply a new causal study.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C32", "text": "MAESTRO-NASH found greater 52-week MASH resolution and fibrosis improvement with resmetirom than placebo in 966 participants. A liver-directed drug establishes its own biopsy efficacy rather than assigned lifestyle efficacy or hard clinical-event prevention.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C33", "text": "SYNERGY-NASH randomized 190 participants and found greater 52-week MASH resolution and fibrosis improvement with tirzepatide, using its missing-biopsy analysis. Drug action is distinct; 157 had follow-up biopsies and an indexed erratum remains linked, whose correction details have not been separately examined.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C34", "text": "LEAN found greater 48-week NASH resolution and less fibrosis progression with liraglutide in a small randomized paired-biopsy trial. Only 45 of 52 had endpoint biopsies; drug and lifestyle mediators are not separated, and less progression is not universal fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C35", "text": "NATIVE found positive activity and selected resolution/fibrosis endpoints with high-dose lanifibranor over 24 weeks despite weight gain. Lower-dose primary significance differed; the result challenges weight-loss necessity for every therapy without refuting lifestyle sufficiency.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C36", "text": "The randomized phase-2 resmetirom trial reduced its MRI-fat primary endpoint over 36 weeks in biopsy-confirmed NASH. The examined abstract does not supply complete secondary biopsy-component evidence; MRI response is not hard-event prevention or isolated weight mediation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C37", "text": "A 124-person biopsy-MASH trial reported better histologic improvement with vitamin E 300 mg than placebo. Drug-specific benefit does not prove assigned lifestyle efficacy, and the abstract does not specify enough timing/component detail to reconstruct every registered histology criterion.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C38", "text": "REGENERATE reported a positive 18-month fibrosis endpoint with higher-dose obeticholic acid while NASH-resolution endpoints were nonsignificant. Fibrosis and active steatohepatitis can dissociate; indexed errata remain attached and their details were not independently audited; pruritus and clinical-event uncertainty matter.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C39", "text": "Pioglitazone versus placebo on matched hypocaloric diet improved NASH histology in 101 prediabetic/diabetic adults over 18 months despite weight gain. The randomized addition is pioglitazone, not diet; weight gain counters universal weight-loss necessity without erasing lifestyle efficacy.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C40", "text": "A target-trial emulation associated some GLP1-based therapies with fewer major adverse liver outcomes over two years, with drug-specific differences. EHR confounding and exposure/diagnosis ascertainment remain; it is not an actual randomized event trial or lifestyle-to-event mediation test.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C41", "text": "SYNERGY-NASH posthoc responder and mediation analyses associated achieved weight/metabolic changes with biopsy response. Shares the parent trial and uses completers/responders; statistical mediation does not randomize weight or establish a necessary isolated mediator.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C42", "text": "A MAESTRO-NASH F2-F3 analysis reports stage-defined histologic benefits of resmetirom. Baseline stage is valid context but the participants share the primary parent and do not create an independent lifestyle or drug causal line.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C43", "text": "FLINT posthoc analysis associated weight change with additive histology responses during obeticholic-acid treatment, with adverse metabolic changes. This is a different OCA parent from REGENERATE; achieved weight is nonrandomized and does not isolate lifestyle causality or weight necessity.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C44", "text": "A 165-person six-month LCHF versus HCLF diabetes trial improved weight and glycemia more with LCHF but found no between-group liver-biopsy NAFLD difference. Not restricted to baseline MASH and no intentional weight-loss assignment; metabolic or weight improvement is not automatic histologic reversal, and benefits waned after diet discontinuation.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C45", "text": "A small biopsy-NAFLD crossover found Mediterranean-diet MRI-fat and insulin-sensitivity improvement without different weight loss. Six-week periods and fat endpoints do not satisfy 24-week paired MASH histology; diet composition may act separately from weight change.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C46", "text": "A small randomized ten-month energy-restriction/HIIT trial reported treatment improvements in inflammation, ballooning and steatohepatitis, while mean fibrosis remained unchanged. Actual Methods/Results define clinical histologic resolution; Results report 9 treatment and 0 control resolutions (final sample 16 and 8), reconcilable with eight treated ballooning-to-0 reductions because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm without a printed between-group test, controls entered with higher MRS liver fat (24% versus 15%), and bundled treatment and correlational mediators preclude isolated weight causality.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS and METHODS:paragraph0, 1:MATERIALS and METHODS:paragraph1, 1:MATERIALS and METHODS:paragraph4, 2:RESULTS:paragraph0, 2:RESULTS:paragraph1, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C47", "text": "A four-arm diet/exercise NAFLD-prediabetes trial linked liver-fat and microbiome changes in 85 of 115 completers over about nine months. No actual follow-up MASH histology or randomized microbial mediator; completer associations cannot establish microbiome necessity or fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C48", "text": "TANGO compared diet strategies in 88 Chinese women and found short-term fat/weight responses. Twelve-week noninvasive outcomes and restricted sex/context do not establish the registered adult MASH histology response.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C49", "text": "A 39-person two-month very-low-calorie ketogenic diet study reduced MRI liver fat and weight. Short exposure, noninvasive fat and different dietary composition cannot establish inflammation/ballooning or fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C50", "text": "A 40-boy randomized free-sugar-restriction trial reduced liver fat over eight weeks in adolescent NAFLD. Children, short follow-up and MRI-fat outcome are outside registered adult MASH biopsy scope; an indexed erratum remains linked rather than counted as an original study.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C51", "text": "LEAN's 14-person mechanism substudy examined clamp and cellular changes during 12 weeks of liraglutide. Shares the LEAN treatment platform; physiological and cell findings do not establish isolated weight mediation, a new clinical histology line or the registered horizon.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C52", "text": "Ipragliflozin versus control in a small 72-week diabetes/NAFLD paired-biopsy trial reported more fibrosis improvement and NASH resolution. A distinct drug in a mixed baseline NAFLD population is not a lifestyle causal comparison; incomplete follow-up biopsies and small numbers limit transfer.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C53", "text": "MAESTRO-NASH reported health-related quality-of-life patterns related to histologic response. Shares the parent and response-defined analysis; functional association does not establish liver-death prevention or independent efficacy.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C54", "text": "A small selected resmetirom extension documented continued noninvasive hepatic/metabolic responses out to 72 weeks. An open-label completer extension shares its phase-2 parent, lacks concurrent randomized control and cannot establish lifestyle or event prevention.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C55", "text": "A matched older-adult MASLD EHR cohort associated GLP1 initiation with lower decompensation and mortality hazards but no lower MACE hazard. Coded diagnoses, residual prescribing confounding and varying follow-up remain; drug associations cannot prove lifestyle or surrogate-to-clinical causality.", "carries_number": true, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C56", "text": "A 64-person pemvidutide extension retained assigned doses and showed greater MRI-fat and weight reductions at 24 weeks. Selected extension completers and imaging endpoints do not establish paired-biopsy MASH/fibrosis or isolate weight versus direct glucagon action.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C57", "text": "MAESTRO-NAFLD-1 randomized resmetirom in presumed NASH and documented safety plus MRI-fat/lipid/stiffness responses over 52 weeks. Different trial from biopsy MAESTRO-NASH; presumed disease and noninvasive endpoints cannot independently prove MASH histologic reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 57 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C58", "text": "Lanifibranor in 38 diabetes/MASLD adults improved hepatic fat and clamp insulin sensitivity over 24 weeks despite modest weight gain. A different metabolic trial lacks the registered paired-biopsy MASH endpoint; positive fat/glycemia cannot be promoted to fibrosis or hard liver events.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2" ], "source_ns": [ 58 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C59", "text": "Resmetirom in biopsy-confirmed diet-induced mouse NASH improved fat/activity and fibrogenic measures without changing weight. Forced diet/model exposure and liver-directed drug do not establish endogenous human weight mechanisms or assigned lifestyle response; alpha-SMA/gene changes are not universal clinical fibrosis proof.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 59 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C60", "text": "Three biopsy-NASH patients showed lower hepatic rpS6 phosphorylation after a 20-week exercise intervention. Uncontrolled tiny marker study is below the registered duration and does not establish pathway necessity, MASH resolution or actual fibrosis reversal.", "carries_number": true, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 60 ], "verification": "verified", "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "verified_on": "2026-10-13", "note": "" }, { "id": "C61", "text": "Eckard et al. 2013 randomized 56 adults with biopsy-proven NAFLD to standard care or one of three diet/exercise arms for six months with repeat biopsy; NAS improved in the 41 completers (88% with NASH) as a whole (p < 0.001) with no difference between arms, standard care included (p = 0.31). A randomized lifestyle-versus-standard-care paired-biopsy contrast was null; mixed NAFLD/NASH entry, completer analysis and small arms limit it, NAS is a composite rather than current resolution criteria, and it does not refute the positive SC2 trial.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 61 ], "verification": "verified", "verified_against": "PubMed abstract and record metadata examined during the 2026-11-02 adversarial pass (added on that pass's finding WL-2); no complete-paper or supplement audit claimed.", "verified_on": "2026-11-02", "note": "Added by adversarial finding WL-2." }, { "id": "CSC1", "text": "Assigned lifestyle in the Promrat paired-biopsy trial reduced steatosis relative to education, and controlled exercise/metabolic work supports direct hepatic-fat change. This is a pathological fat component crossing within its measured scope, not a substitution of fat for steatohepatitis or hard-event benefit. The disease-stage and mediator boundaries prevent high-ladder generalization.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 32, 33, 34, 35, 36, 39, 41, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 54, 56, 57, 58, 59, 60 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC2", "text": "The newer randomized energy-restriction/HIIT trial explicitly defines histologic resolution by inflammation 0–1 and ballooning 0, and reports improvements in these components and steatohepatitis relative to its control trajectory at about ten months. This supplies a first direct assigned clinical phenotype perturbation. Its Results report resolution in 9 treatment and 0 control participants (final sample 16 and 8); the eight treated participants who reduced ballooning to 0 are compatible with nine resolutions because entry required NAS of at least 4, not ballooning of at least 1. Its small final sample, within-arm component reporting without a printed between-group test, and higher baseline MRS liver fat in controls (24% versus 15%) constrain confidence. Promrat improves a composite NAS and steatosis but has nonsignificant assigned component differences, so it reinforces activity change without being counted as a second current-resolution confirmation. The other randomized standard-care-controlled paired-biopsy lifestyle trial found on targeted search (Eckard 2013) showed improvement in every arm without a between-arm difference, so the assigned-package effect is not yet consistently reproduced. Broader clinical contexts and isolated weight mediation remain unestablished.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 15, 16, 17, 18, 19, 20, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC3", "text": "Fibrosis is biologically and clinically modifiable by some interventions, and lifestyle cohorts associate substantial achieved loss with regression. However, both examined lifestyle-trial bodies report no significant average fibrosis change. Nonrandom achieved-loss strata and selected individual improvements cannot replace a positive controlled assigned-fibrosis result. Surgery and drug fibrosis positives demonstrate those exposures rather than lifestyle reversal.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 1, 2, 3, 4, 6, 7, 9, 10, 11, 12, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, 52, 53, 54, 55, 56, 57, 59, 60 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CSC4", "text": "Liver-fat, ALT or histologic biomarker improvement does not itself establish prevention of cirrhosis or liver death. Bariatric and GLP1 event cohorts are separate observational exposure evidence. The small cirrhosis drug body shows fat and weight reductions alongside null histology and no observed decompensation; absence of events in a short small trial is not prevention proof. The proxy-to-hard-clinical inference remains capped.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 3, 4, 11, 23, 24, 26, 27, 38, 40, 53, 55 ], "verification": "verified", "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.", "verified_on": "2026-10-13", "note": "" }, { "id": "CH", "text": "Lifestyle treatment can improve MASH histology; fibrosis reversal, liver-death prevention and weight loss as the sole mediator require stronger direct evidence.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 46, 1, 2, 24, 27 ], "verification": "verified", "verified_against": "Bounded synthesis of examined sources; score is adjudication.", "verified_on": "2026-10-13", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2010.", "tier": "A", "kind": "rct", "pmid": "19827166", "doi": "10.1002/hep.23276", "url": "https://pubmed.ncbi.nlm.nih.gov/19827166/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PROMRAT-LIFESTYLE", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph0, 0:Methods:paragraph1, 0:Methods:paragraph2, 0:Methods:paragraph11, 0:Methods:paragraph13, 0:Methods:paragraph14, 1:Results:paragraph0, 1:Results:paragraph1, 1:Results:paragraph6, 1:Results:paragraph7, 1:Results:paragraph8, 1:Results:paragraph9, 1:Results:paragraph12. No complete-paper or supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC2", "CSC3", "CH" ] }, { "n": 2, "citation": "Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015.", "tier": "A", "kind": "primary", "pmid": "25865049", "doi": "10.1053/j.gastro.2015.04.005", "url": "https://pubmed.ncbi.nlm.nih.gov/25865049/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C2", "CSC1", "CSC2", "CSC3", "CH" ] }, { "n": 3, "citation": "Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology (Baltimore, Md.). 2016.", "tier": "A", "kind": "primary", "pmid": "26849287", "doi": "10.1002/hep.28484", "url": "https://pubmed.ncbi.nlm.nih.gov/26849287/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C3", "CSC2", "CSC3", "CSC4" ] }, { "n": 4, "citation": "Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL et al. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2017.", "tier": "A", "kind": "primary", "pmid": "27862096", "doi": "10.1111/apt.13860", "url": "https://pubmed.ncbi.nlm.nih.gov/27862096/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C4", "CSC2", "CSC3", "CSC4" ] }, { "n": 5, "citation": "Promrat K, Longato L, Wands JR et al. Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatology research : the official journal of the Japan Society of Hepatology. 2011.", "tier": "A", "kind": "primary", "pmid": "21794038", "doi": "10.1111/j.1872-034X.2011.00815.x", "url": "https://pubmed.ncbi.nlm.nih.gov/21794038/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PROMRAT-LIFESTYLE", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C5", "CSC1", "CSC2" ] }, { "n": 6, "citation": "Houghton D, Thoma C, Hallsworth K et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017.", "tier": "A", "kind": "rct", "pmid": "27521509", "doi": "10.1016/j.cgh.2016.07.031", "url": "https://pubmed.ncbi.nlm.nih.gov/27521509/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27521509", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C6", "CSC1", "CSC2", "CSC3" ] }, { "n": 7, "citation": "Cuthbertson DJ, Keating SE, Pugh CJA et al. Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease. Liver international : official journal of the International Association for the Study of the Liver. 2024.", "tier": "A", "kind": "primary", "pmid": "38847589", "doi": "10.1111/liv.15947", "url": "https://pubmed.ncbi.nlm.nih.gov/38847589/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38847589", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C7", "CSC1", "CSC2", "CSC3" ] }, { "n": 8, "citation": "Hallsworth K, Thoma C, Hollingsworth KG et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clinical science (London, England : 1979). 2015.", "tier": "A", "kind": "rct", "pmid": "26265792", "doi": "10.1042/CS20150308", "url": "https://pubmed.ncbi.nlm.nih.gov/26265792/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26265792", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C8", "CSC1", "CSC2" ] }, { "n": 9, "citation": "Katsagoni CN, Papatheodoridis GV, Ioannidou P et al. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. The British journal of nutrition. 2018.", "tier": "A", "kind": "rct", "pmid": "29947322", "doi": "10.1017/S000711451800137X", "url": "https://pubmed.ncbi.nlm.nih.gov/29947322/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29947322", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C9", "CSC1", "CSC3" ] }, { "n": 10, "citation": "Ezpeleta M, Gabel K, Cienfuegos S et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell metabolism. 2023.", "tier": "A", "kind": "rct", "pmid": "36549296", "doi": "10.1016/j.cmet.2022.12.001", "url": "https://pubmed.ncbi.nlm.nih.gov/36549296/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36549296", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C10", "CSC1", "CSC2", "CSC3" ] }, { "n": 11, "citation": "Dallio M, Romeo M, Di Nardo F et al. A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial. Clinical nutrition (Edinburgh, Scotland). 2026.", "tier": "A", "kind": "primary", "pmid": "42805146", "doi": "10.1016/j.clnu.2026.106800", "url": "https://pubmed.ncbi.nlm.nih.gov/42805146/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42805146", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C11", "CSC1", "CSC3", "CSC4" ] }, { "n": 12, "citation": "Wu Y, Li L, Zhang X et al. Isocaloric-restricted traditional Jiangnan diet combined with physical exercise on non-alcoholic fatty liver disease: a randomized controlled trial. Nutrition & metabolism. 2026.", "tier": "A", "kind": "primary", "pmid": "41933392", "doi": "10.1186/s12986-026-01105-4", "url": "https://pubmed.ncbi.nlm.nih.gov/41933392/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41933392", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC3" ] }, { "n": 13, "citation": "Scaglioni F, Marino M, Ciccia S et al. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and research in hepatology and gastroenterology. 2013.", "tier": "A", "kind": "primary", "pmid": "23273500", "doi": "10.1016/j.clinre.2012.10.009", "url": "https://pubmed.ncbi.nlm.nih.gov/23273500/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23273500", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C13", "CSC1" ] }, { "n": 14, "citation": "Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Alimentary pharmacology & therapeutics. 2009.", "tier": "A", "kind": "rct", "pmid": "19691668", "doi": "10.1111/j.1365-2036.2009.04122.x", "url": "https://pubmed.ncbi.nlm.nih.gov/19691668/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID19691668", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C14", "CSC1", "CSC2", "CSC3" ] }, { "n": 15, "citation": "Harrison SA, Fincke C, Helinski D et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Alimentary pharmacology & therapeutics. 2004.", "tier": "A", "kind": "rct", "pmid": "15352910", "doi": "10.1111/j.1365-2036.2004.02153.x", "url": "https://pubmed.ncbi.nlm.nih.gov/15352910/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID15352910", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C15", "CSC1", "CSC2", "CSC3" ] }, { "n": 16, "citation": "Lee YM, Low HC, Lim LG et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointestinal endoscopy. 2012.", "tier": "A", "kind": "rct", "pmid": "22840293", "doi": "10.1016/j.gie.2012.05.023", "url": "https://pubmed.ncbi.nlm.nih.gov/22840293/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID22840293", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C16", "CSC1", "CSC2", "CSC3" ] }, { "n": 17, "citation": "Abad J, Llop E, Arias-Loste MT et al. Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2025.", "tier": "A", "kind": "rct", "pmid": "39694202", "doi": "10.1016/j.cgh.2024.10.027", "url": "https://pubmed.ncbi.nlm.nih.gov/39694202/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39694202", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C17", "CSC1", "CSC2", "CSC3" ] }, { "n": 18, "citation": "Noureddin M, Rinella M, Taub R et al. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Alimentary pharmacology & therapeutics. 2025.", "tier": "A", "kind": "rct", "pmid": "41127972", "doi": "10.1111/apt.70382", "url": "https://pubmed.ncbi.nlm.nih.gov/41127972/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C18", "CSC1", "CSC2", "CSC3" ] }, { "n": 19, "citation": "Bomhof MR, Parnell JA, Ramay HR et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. European journal of nutrition. 2019.", "tier": "A", "kind": "rct", "pmid": "29779170", "doi": "10.1007/s00394-018-1721-2", "url": "https://pubmed.ncbi.nlm.nih.gov/29779170/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID29779170", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C19", "CSC1", "CSC2" ] }, { "n": 20, "citation": "Wong VW, Neff GW, Di Bisceglie AM et al. HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. Clinical and molecular hepatology. 2025.", "tier": "A", "kind": "rct", "pmid": "40258699", "doi": "10.3350/cmh.2025.0145", "url": "https://pubmed.ncbi.nlm.nih.gov/40258699/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40258699", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C20", "CSC1", "CSC2", "CSC3" ] }, { "n": 21, "citation": "Saadati S, Hatami B, Yari Z et al. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. European journal of clinical nutrition. 2019.", "tier": "A", "kind": "rct", "pmid": "30610213", "doi": "10.1038/s41430-018-0382-9", "url": "https://pubmed.ncbi.nlm.nih.gov/30610213/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30610213", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C21", "CSC1", "CSC3" ] }, { "n": 22, "citation": "Aller R, Izaola O, Gómez S et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. European review for medical and pharmacological sciences. 2015.", "tier": "A", "kind": "rct", "pmid": "26367736", "doi": null, "doi_note": "not indexed in PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/26367736/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID26367736", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C22", "CSC1", "CSC3" ] }, { "n": 23, "citation": "Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. The New England journal of medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "40305708", "doi": "10.1056/NEJMoa2413258", "url": "https://pubmed.ncbi.nlm.nih.gov/40305708/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40305708", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C23", "CSC1", "CSC2", "CSC3", "CSC4" ] }, { "n": 24, "citation": "Loomba R, Abdelmalek MF, Armstrong MJ et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The lancet. Gastroenterology & hepatology. 2023.", "tier": "A", "kind": "rct", "pmid": "36934740", "doi": "10.1016/S2468-1253(23)00068-7", "url": "https://pubmed.ncbi.nlm.nih.gov/36934740/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36934740", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph7, 1:Methods:paragraph10, 1:Methods:paragraph11, 1:Methods:paragraph15, 2:Results:paragraph5, 2:Results:paragraph8, 2:Results:paragraph9, 2:Results:paragraph11, 2:Results:paragraph15, 2:Results:paragraph24. No complete-paper or supplement audit claimed.", "carries_claims": [ "C24", "CSC1", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 25, "citation": "Newsome PN, Buchholtz K, Cusi K et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. The New England journal of medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "33185364", "doi": "10.1056/NEJMoa2028395", "url": "https://pubmed.ncbi.nlm.nih.gov/33185364/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SEMA-DAILY-NCT02970942", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C25", "CSC1", "CSC2", "CSC3" ] }, { "n": 26, "citation": "Lassailly G, Caiazzo R, Ntandja-Wandji LC et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020.", "tier": "A", "kind": "primary", "pmid": "32553765", "doi": "10.1053/j.gastro.2020.06.006", "url": "https://pubmed.ncbi.nlm.nih.gov/32553765/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32553765", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C26", "CSC1", "CSC2", "CSC3", "CSC4" ] }, { "n": 27, "citation": "Aminian A, Al-Kurd A, Wilson R et al. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA. 2021.", "tier": "A", "kind": "primary", "pmid": "34762106", "doi": "10.1001/jama.2021.19569", "url": "https://pubmed.ncbi.nlm.nih.gov/34762106/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34762106", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C27", "CSC2", "CSC3", "CSC4", "CH" ] }, { "n": 28, "citation": "Flint A, Andersen G, Hockings P et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Alimentary pharmacology & therapeutics. 2021.", "tier": "A", "kind": "rct", "pmid": "34570916", "doi": "10.1111/apt.16608", "url": "https://pubmed.ncbi.nlm.nih.gov/34570916/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34570916", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C28", "CSC1", "CSC2", "CSC3" ] }, { "n": 29, "citation": "Verrastro O, Panunzi S, Castagneto-Gissey L et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet (London, England). 2023.", "tier": "A", "kind": "rct", "pmid": "37088093", "doi": "10.1016/S0140-6736(23)00634-7", "url": "https://pubmed.ncbi.nlm.nih.gov/37088093/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID37088093", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C29", "CSC1", "CSC2", "CSC3" ] }, { "n": 30, "citation": "Alkhouri N, Herring R, Kabler H et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of hepatology. 2022.", "tier": "A", "kind": "rct", "pmid": "35439567", "doi": "10.1016/j.jhep.2022.04.003", "url": "https://pubmed.ncbi.nlm.nih.gov/35439567/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35439567", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C30", "CSC1", "CSC2", "CSC3" ] }, { "n": 31, "citation": "Ratziu V, Francque S, Behling CA et al. Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2024.", "tier": "A", "kind": "rct", "pmid": "38112484", "doi": "10.1097/HEP.0000000000000723", "url": "https://pubmed.ncbi.nlm.nih.gov/38112484/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SEMA-DAILY-NCT02970942", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C31", "CSC2", "CSC3" ] }, { "n": 32, "citation": "Harrison SA, Bedossa P, Guy CD et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38324483", "doi": "10.1056/NEJMoa2309000", "url": "https://pubmed.ncbi.nlm.nih.gov/38324483/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C32", "CSC1", "CSC2", "CSC3" ] }, { "n": 33, "citation": "Loomba R, Hartman ML, Lawitz EJ et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England journal of medicine. 2024.", "tier": "A", "kind": "rct", "pmid": "38856224", "doi": "10.1056/NEJMoa2401943", "url": "https://pubmed.ncbi.nlm.nih.gov/38856224/", "status_flags": [ "Erratum In: PMID41880634" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SYNERGY-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C33", "CSC1", "CSC2", "CSC3" ] }, { "n": 34, "citation": "Armstrong MJ, Gaunt P, Aithal GP et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England). 2016.", "tier": "A", "kind": "rct", "pmid": "26608256", "doi": "10.1016/S0140-6736(15)00803-X", "url": "https://pubmed.ncbi.nlm.nih.gov/26608256/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "LEAN", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C34", "CSC1", "CSC2", "CSC3" ] }, { "n": 35, "citation": "Francque SM, Bedossa P, Ratziu V et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. The New England journal of medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "34670042", "doi": "10.1056/NEJMoa2036205", "url": "https://pubmed.ncbi.nlm.nih.gov/34670042/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34670042", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C35", "CSC1", "CSC2", "CSC3" ] }, { "n": 36, "citation": "Harrison SA, Bashir MR, Guy CD et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England). 2019.", "tier": "A", "kind": "rct", "pmid": "31727409", "doi": "10.1016/S0140-6736(19)32517-6", "url": "https://pubmed.ncbi.nlm.nih.gov/31727409/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RESMET-PHASE2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C36", "CSC1", "CSC2", "CSC3" ] }, { "n": 37, "citation": "Song Y, Ni W, Zheng M et al. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study. Cell reports. Medicine. 2025.", "tier": "A", "kind": "rct", "pmid": "39970876", "doi": "10.1016/j.xcrm.2025.101939", "url": "https://pubmed.ncbi.nlm.nih.gov/39970876/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39970876", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C37", "CSC2", "CSC3" ] }, { "n": 38, "citation": "Younossi ZM, Ratziu V, Loomba R et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2019.", "tier": "A", "kind": "rct", "pmid": "31813633", "doi": "10.1016/S0140-6736(19)33041-7", "url": "https://pubmed.ncbi.nlm.nih.gov/31813633/", "status_flags": [ "Erratum In: PMID32738952", "Erratum In: PMID34147150" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "REGENERATE", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C38", "CSC2", "CSC3", "CSC4" ] }, { "n": 39, "citation": "Cusi K, Orsak B, Bril F et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Annals of internal medicine. 2016.", "tier": "A", "kind": "rct", "pmid": "27322798", "doi": "10.7326/M15-1774", "url": "https://pubmed.ncbi.nlm.nih.gov/27322798/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID27322798", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C39", "CSC1", "CSC2", "CSC3" ] }, { "n": 40, "citation": "Henney AE, Riley DR, Anson M et al. Target Trial Emulations of GLP-1 and Dual GLP-1/GIP Agonists to Reduce Major Adverse Liver Outcomes in Type 2 Diabetes. Liver international : official journal of the International Association for the Study of the Liver. 2025.", "tier": "A", "kind": "primary", "pmid": "40980971", "doi": "10.1111/liv.70367", "url": "https://pubmed.ncbi.nlm.nih.gov/40980971/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID40980971", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C40", "CSC2", "CSC3", "CSC4" ] }, { "n": 41, "citation": "Caussy C, Cusi K, Rosenstock J et al. Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide. Diabetes care. 2025.", "tier": "A", "kind": "rct", "pmid": "41066427", "doi": "10.2337/dc25-1306", "url": "https://pubmed.ncbi.nlm.nih.gov/41066427/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "SYNERGY-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C41", "CSC1", "CSC2", "CSC3" ] }, { "n": 42, "citation": "Mironova M, Padmanabhan K, Schneider D et al. Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset. Alimentary pharmacology & therapeutics. 2026.", "tier": "A", "kind": "rct", "pmid": "42527732", "doi": "10.1111/apt.70888", "url": "https://pubmed.ncbi.nlm.nih.gov/42527732/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C42", "CSC2", "CSC3" ] }, { "n": 43, "citation": "Hameed B, Terrault NA, Gill RM et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2018.", "tier": "A", "kind": "rct", "pmid": "29333665", "doi": "10.1111/apt.14492", "url": "https://pubmed.ncbi.nlm.nih.gov/29333665/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "FLINT-NCT01265498", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C43", "CSC1", "CSC2", "CSC3" ] }, { "n": 44, "citation": "Hansen CD, Gram-Kampmann EM, Hansen JK et al. Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial. Annals of internal medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "36508737", "doi": "10.7326/M22-1787", "url": "https://pubmed.ncbi.nlm.nih.gov/36508737/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID36508737", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C44", "CSC1", "CSC2", "CSC3" ] }, { "n": 45, "citation": "Ryan MC, Itsiopoulos C, Thodis T et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. Journal of hepatology. 2013.", "tier": "A", "kind": "rct", "pmid": "23485520", "doi": "10.1016/j.jhep.2013.02.012", "url": "https://pubmed.ncbi.nlm.nih.gov/23485520/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID23485520", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C45", "CSC1", "CSC2" ] }, { "n": 46, "citation": "Mucinski JM, Salvador AF, Moore MP et al. Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH. Journal of hepatology. 2024.", "tier": "A", "kind": "rct", "pmid": "38914313", "doi": "10.1016/j.jhep.2024.06.017", "url": "https://pubmed.ncbi.nlm.nih.gov/38914313/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "NCT03151798", "access_depth": "full_text_partial", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS and METHODS:paragraph0, 1:MATERIALS and METHODS:paragraph1, 1:MATERIALS and METHODS:paragraph4, 2:RESULTS:paragraph0, 2:RESULTS:paragraph1, 2:RESULTS:paragraph4, 2:RESULTS:paragraph5. No complete-paper or supplement audit claimed.", "carries_claims": [ "C46", "CSC1", "CSC2", "CSC3", "CH" ] }, { "n": 47, "citation": "Cheng R, Wang L, Le S et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease. Nature communications. 2022.", "tier": "A", "kind": "rct", "pmid": "35538056", "doi": "10.1038/s41467-022-29968-0", "url": "https://pubmed.ncbi.nlm.nih.gov/35538056/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID35538056", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C47", "CSC1", "CSC2" ] }, { "n": 48, "citation": "Chooi YC, Zhang QA, Magkos F et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. The American journal of clinical nutrition. 2024.", "tier": "A", "kind": "rct", "pmid": "38035997", "doi": "10.1016/j.ajcnut.2023.11.013", "url": "https://pubmed.ncbi.nlm.nih.gov/38035997/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID38035997", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C48", "CSC1", "CSC2" ] }, { "n": 49, "citation": "Cunha GM, Guzman G, Correa De Mello LL et al. Efficacy of a 2-Month Very Low-Calorie Ketogenic Diet (VLCKD) Compared to a Standard Low-Calorie Diet in Reducing Visceral and Liver Fat Accumulation in Patients With Obesity. Frontiers in endocrinology. 2020.", "tier": "A", "kind": "rct", "pmid": "33042004", "doi": "10.3389/fendo.2020.00607", "url": "https://pubmed.ncbi.nlm.nih.gov/33042004/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33042004", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C49", "CSC1", "CSC2" ] }, { "n": 50, "citation": "Schwimmer JB, Ugalde-Nicalo P, Welsh JA et al. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019.", "tier": "A", "kind": "rct", "pmid": "30667502", "doi": "10.1001/jama.2018.20579", "url": "https://pubmed.ncbi.nlm.nih.gov/30667502/", "status_flags": [ "Erratum In: PMID31386114" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID30667502", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C50", "CSC1", "CSC2" ] }, { "n": 51, "citation": "Armstrong MJ, Hull D, Guo K et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of hepatology. 2016.", "tier": "A", "kind": "rct", "pmid": "26394161", "doi": "10.1016/j.jhep.2015.08.038", "url": "https://pubmed.ncbi.nlm.nih.gov/26394161/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "LEAN", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C51", "CSC1", "CSC2" ] }, { "n": 52, "citation": "Takahashi H, Kessoku T, Kawanaka M et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatology communications. 2022.", "tier": "A", "kind": "rct", "pmid": "34558835", "doi": "10.1002/hep4.1696", "url": "https://pubmed.ncbi.nlm.nih.gov/34558835/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID34558835", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C52", "CSC1", "CSC2", "CSC3" ] }, { "n": 53, "citation": "Younossi ZM, Stepanova M, Racila A et al. Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. Hepatology (Baltimore, Md.). 2025.", "tier": "A", "kind": "rct", "pmid": "39250515", "doi": "10.1097/HEP.0000000000001084", "url": "https://pubmed.ncbi.nlm.nih.gov/39250515/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NASH", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C53", "CSC2", "CSC3", "CSC4" ] }, { "n": 54, "citation": "Harrison SA, Bashir M, Moussa SE et al. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH. Hepatology communications. 2021.", "tier": "A", "kind": "rct", "pmid": "33860116", "doi": "10.1002/hep4.1657", "url": "https://pubmed.ncbi.nlm.nih.gov/33860116/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "RESMET-PHASE2", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C54", "CSC1", "CSC2", "CSC3" ] }, { "n": 55, "citation": "Koutouratsas T, Kalligeros M, Michael M et al. GLP-1-based treatments and long-term clinical outcomes in MASLD amongst older adults: a retrospective cohort study. Age and ageing. 2026.", "tier": "A", "kind": "primary", "pmid": "42765724", "doi": "10.1093/ageing/afag281", "url": "https://pubmed.ncbi.nlm.nih.gov/42765724/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID42765724", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C55", "CSC2", "CSC3", "CSC4" ] }, { "n": 56, "citation": "Browne SK, Suschak JJ, Tomah S et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP reports : innovation in hepatology. 2025.", "tier": "A", "kind": "primary", "pmid": "41113119", "doi": "10.1016/j.jhepr.2025.101483", "url": "https://pubmed.ncbi.nlm.nih.gov/41113119/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID41113119", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C56", "CSC1", "CSC2", "CSC3" ] }, { "n": 57, "citation": "Harrison SA, Taub R, Neff GW et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37845512", "doi": "10.1038/s41591-023-02603-1", "url": "https://pubmed.ncbi.nlm.nih.gov/37845512/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "MAESTRO-NAFLD1", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C57", "CSC1", "CSC2", "CSC3" ] }, { "n": 58, "citation": "Barb D, Kalavalapalli S, Godinez Leiva E et al. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of hepatology. 2025.", "tier": "A", "kind": "rct", "pmid": "39824443", "doi": "10.1016/j.jhep.2024.12.045", "url": "https://pubmed.ncbi.nlm.nih.gov/39824443/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID39824443", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C58", "CSC1", "CSC2" ] }, { "n": 59, "citation": "Kannt A, Wohlfart P, Madsen AN et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. British journal of pharmacology. 2021.", "tier": "A", "kind": "primary", "pmid": "33655500", "doi": "10.1111/bph.15427", "url": "https://pubmed.ncbi.nlm.nih.gov/33655500/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID33655500", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C59", "CSC1", "CSC2", "CSC3" ] }, { "n": 60, "citation": "Stine JG, Xu D, Schmitz K et al. Exercise Attenuates Ribosomal Protein Six Phosphorylation in Fatty Liver Disease. Digestive diseases and sciences. 2020.", "tier": "A", "kind": "primary", "pmid": "32239376", "doi": "10.1007/s10620-020-06226-1", "url": "https://pubmed.ncbi.nlm.nih.gov/32239376/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-13", "status_checked_on": "2026-10-13", "study_id": "PMID32239376", "access_depth": "abstract_metadata", "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.", "carries_claims": [ "C60", "CSC1", "CSC2", "CSC3" ] }, { "n": 61, "citation": "Eckard C, Cole R, Lockwood J et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic advances in gastroenterology. 2013.", "tier": "A", "kind": "rct", "pmid": "23814606", "doi": "10.1177/1756283X13484078", "url": "https://pubmed.ncbi.nlm.nih.gov/23814606/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-11-02", "status_checked_on": "2026-11-02", "study_id": "PMID23814606", "access_depth": "abstract_metadata", "access_note": "PubMed abstract and record metadata examined during the 2026-11-02 adversarial pass (added on that pass's finding WL-2); no complete-paper or supplement audit claimed.", "carries_claims": [ "C61", "CSC2" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "No claim reaches Ζ. Separate small lifestyle studies use different packages and histology definitions; Promrat does not independently confirm the newer current-resolution component endpoint. Replicated or multiple drug/surgery successes are not multiple independent causal lines on assigned lifestyle or isolated weight. Shared trial secondary reports remain single units." }, "gamma_hard_rules_considered": [ { "subclaim_id": "SC1", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC1", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC2", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC3", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "ROS change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "NAD level change measurements alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Mitochondrial metrics alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Senescence marker changes alone", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Single-species or single-strain evidence", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." }, { "subclaim_id": "SC4", "rule_quoted": "Biomarker-only improvement without organismal benefit", "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale." } ], "consensus_validation": { "completed": true, "status": "completed_original_source_reconciliation", "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings", "queries": [ "https://consensus.app/search/lifestyle-weight-loss-effects-mash-nash/dhDOxn4vQh-P6_deE-g-Ug/" ], "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.", "primary_comparison_count": 9, "primary_comparisons": [ { "pmid": "19827166", "doi": "10.1002/hep.23276", "source_type": "primary study report", "study_group": "PROMRAT-LIFESTYLE", "access_depth": "full_text_partial", "consensus_aspect": "Assigned NAS response versus current resolution", "result_comparison": "Observed Consensus calls the NAS composite activity reversal and its minimal-criteria count resolution. Actual Methods define improvement as a three-point NAS drop or NAS at most two; actual Results show assigned NAS/steatosis benefit but nonsignificant assigned inflammation/ballooning differences. This is genuine activity efficacy, not automatically a current inflammation/ballooning resolution result.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/19827166/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-0-8-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\19827166-s0-p0-1-2-11-13-14.json", "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\19827166-s1-p0-1-6-7-8-9-12.json" ] }, { "pmid": "19827166", "doi": "10.1002/hep.23276", "source_type": "primary study report", "study_group": "PROMRAT-LIFESTYLE", "access_depth": "full_text_partial", "consensus_aspect": "Achieved-loss component threshold", "result_comparison": "Provider describes an apparent seven-percent loss threshold. Actual Results place the broader component positives in achieved-at-least-seven-percent strata, while the randomized component contrasts were nonsignificant. The weight threshold is nonrandomized association; it is not assigned-dose necessity, a baseline eligibility boundary or justification to exclude nonresponders.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/19827166/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-0-8-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\19827166-s0-p0-1-2-11-13-14.json", "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\19827166-s1-p0-1-6-7-8-9-12.json" ] }, { "pmid": "19827166", "doi": "10.1002/hep.23276", "source_type": "primary study report", "study_group": "PROMRAT-LIFESTYLE", "access_depth": "full_text_partial", "consensus_aspect": "Paired-biopsy completion and histology estimand", "result_comparison": "Provider gives 31 randomized participants and percentages but omits actual endpoint-biopsy availability. Original Results show 28 of 31 with paired biopsy: 18 of 21 lifestyle and all 10 controls. Therefore its 72-versus-30-percent composite is an available-biopsy comparison, not a silent 31-person complete-pathology audit; missingness and small power limit certainty.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/19827166/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-0-8-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\19827166-s0-p0-1-2-11-13-14.json", "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\19827166-s1-p0-1-6-7-8-9-12.json" ] }, { "pmid": "38914313", "doi": "10.1016/j.jhep.2024.06.017", "source_type": "primary study report", "study_group": "NCT03151798", "access_depth": "full_text_partial", "consensus_aspect": "Provider claim of a single small randomized lifestyle trial", "result_comparison": "Provider identifies Promrat as the only small randomized lifestyle histology trial. The examined newer original Methods/Results contain a randomized ten-month energy-restriction/HIIT comparison with explicit inflammation/ballooning resolution and activity benefit. Provider corpus omission cannot establish absence. Original Results report 9 treatment and 0 control resolutions (final sample 16 and 8; the Discussion gives 56%) and eight treated participants reducing ballooning to 0, which reconcile because entry required NAS of at least 4 rather than ballooning of at least 1; component changes are reported within arm, with no printed between-group test and higher baseline liver fat in controls.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/38914313/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-38-46-10000.json", "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-45-46-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\38914313-s1-p0-1-4.json", "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\38914313-s2-p0-1-4-5.json" ] }, { "pmid": "25865049", "doi": "10.1053/j.gastro.2015.04.005", "source_type": "primary study report", "study_group": "VILAR-LIFESTYLE-293", "access_depth": "abstract_metadata", "consensus_aspect": "Achieved-loss cohort and shared prediction report", "result_comparison": "Provider correctly distinguishes the nonrandomized cohort and larger achieved-loss response. The examined original abstract reports 293 enrolled and 261 paired biopsies with subgroup resolution/regression associations. The follow-up prediction PMID26849287 shares that cohort; different subgroup counts or prediction models do not constitute a new causal trial. No complete cohort body was examined.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/25865049/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-0-8-10000.json" ], "body_receipts": [] }, { "pmid": "37088093", "doi": "10.1016/S0140-6736(23)00634-7", "source_type": "primary study report", "study_group": "PMID37088093", "access_depth": "abstract_metadata", "consensus_aspect": "Surgery superiority versus standalone lifestyle causal efficacy", "result_comparison": "Provider correctly retains BRAVES surgery superiority. The original trial abstract distinguishes ITT and available-protocol response rates. Lifestyle plus best medical care is a comparator to surgery, so its response percentage cannot establish efficacy versus untreated patients or isolate lifestyle weight mediation. Surgery adverse events remain part of its separate evidence.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/37088093/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-22-30-10000.json" ], "body_receipts": [] }, { "pmid": "32553765", "doi": "10.1053/j.gastro.2020.06.006", "source_type": "primary study report", "study_group": "PMID32553765", "access_depth": "abstract_metadata", "consensus_aspect": "Long-term bariatric biopsies and selection", "result_comparison": "Provider treats five-year surgery biopsy benefit as distinct from lifestyle and reports incomplete biopsy availability. The examined original abstract supports substantial observed resolution/regression with 64 of 94 five-year-eligible patients biopsied. It is selected uncontrolled long-term surgery, outside the registered 24–104-week lifestyle primary; absence of statistically different observed groups does not rule out unmeasured nonresponse bias.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/32553765/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-22-30-10000.json" ], "body_receipts": [] }, { "pmid": "36934740", "doi": "10.1016/S2468-1253(23)00068-7", "source_type": "primary study report", "study_group": "PMID36934740", "access_depth": "full_text_partial", "consensus_aspect": "Fat/weight improvement versus actual clinical histology in cirrhosis", "result_comparison": "Provider discusses component dissociation largely through older trials and reviews, with recent originals absent from its indexed text. The selected F4 semaglutide original Methods/Results directly show significant weight/MRI-fat reduction but null biopsy resolution/fibrosis at 48 weeks, differential biopsy availability and no decompensation events. This is a stage/drug boundary; it neither proves lifestyle failure nor event prevention from biomarkers.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/36934740/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-22-30-10000.json" ], "body_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\36934740-s1-p1-4-7-10-11-15.json", "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\body-presentation-receipts\\36934740-s2-p5-8-9-11-15-24.json" ] }, { "pmid": "40305708", "doi": "10.1056/NEJMoa2413258", "source_type": "primary study report", "study_group": "PMID40305708", "access_depth": "abstract_metadata", "consensus_aspect": "Provider corpus cutoff and modern positive trials", "result_comparison": "Provider explicitly lacks ESSENCE, SYNERGY-NASH and MAESTRO-NASH primary details. Examined original abstracts PMID40305708,38856224,38324483 retain genuine respective clinical-pathology positives. A review search cutoff is not the present evidence cutoff, and those drug effects cannot be borrowed as lifestyle or isolated-weight causal lines.", "original_source": "https://pubmed.ncbi.nlm.nih.gov/40305708/", "source_examination_receipts": [ "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\examinations\\original-22-30-10000.json" ], "body_receipts": [] } ], "grade_changed": false, "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.", "raw_receipts": [ { "path": "deliverables\\hsef_v53_traffic_ranks_11_15_2026-10-13\\weight-loss-mash-reversal\\consensus-browser-2026-10-13.json", "sha256": "2d936b3364f46ee14f507774fd5fbba4223512dd82882f2fa55ef3a9fad2850b" } ], "independent_blinded_audit": false, "cutoff": "2026-10-13", "completed_utc": "2026-10-13T17:02:53.663494+00:00", "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them." } }